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ABSTRACT
Recurrent head and neck cancer is a disease which causes significant 
morbidity and mortality. Despite advances in surgical reconstruction and in 
chemotherapy and radiotherapy, current treatments for this disease give poor 
responses which are of short duration. Because of this, there is a need for 
new biological therapies to be developed. An example of this is the E lB  
deleted adenovirus, Onyx-015, which has been shown to selectively 
replicate in and lyse cells with non-functional p53 (Bischoff et al,1996). 
This virus may be therapeutically useful in the treatment of a wide range of 
tumours since p53 abnormalities are very common in human cancer. The 
aims of this thesis were to determine if this virus would selectively replicate 
in and lyse head and neck squamous cell carcinoma cell lines with non­
functional p53, to determine if the virus could cause tumour regression of 
subcutaneous tumours derived from human head and neck tumour cell lines 
in a nude mouse xenograft model, and lastly to determine if this virus could 
be given safely by intratumoural injection to patients with recurrent head 
and neck cancer and whether it could produce an anti-tumour response.
Using a panel of human head and neck squamous cell carcinoma cell 
lines of known p53 sequence and function, replication of the E lB  attenuated 
adenovirus, Onyx-015, was tested by cytopathic effect assays, hexon protein 
staining and quantified by flow cytometry. These assays showed that 
replication was more efficient in cell lines with non-functional p53 
confirming the previously published work in other cell types by Bischoff et 
al,1996. The cell line BICR16, derived from a patient with recurrent head 
and neck cancer, was used for in-vivo testing by intratumoural injection of
subcutaneous xenografts in nude mice. We showed tumour regression in all 
virus injected tumours. In contrast, diluent injected tumours continued to 
grow exponentially.
To determine the incidence of p53 inactivation in recurrent head and 
neck cancer, the p53 status of 22 recurrent head and neck tumours was 
evaluated by gene sequencing, mdm2 expression and HPV expression. 
Overall we have shown that there is a greater incidence of p53 mutations in 
recurrent disease compared to primary disease. However the incidence of 
HPV infection and mdm2 overexpression was similar to reported studies in 
primary disease. Nevertheless, we show that the overall incidence of p53 
alterations is very high at 95%. This may be one factor which accounts for 
the poor response of this disease to radiotherapy and chemotherapy and 
implies new therapies which either restore p53 function or which act in a 
p53 independent manner may prove to be beneficial in this disease. Thus 
recurrent head and neck cancer was considered to be a suitable tumour type 
in which to carry out a phase I study using Onyx-015.
Two phase I trials were carried out - a single intratumoural injection 
protocol and a multiple ( 5 daily injections) intratumoural injection protocol. 
The phase I trial by single intratumoural injection was carried out in 22 
patients with recurrent head and neck cancer. Six cohorts were investigated, 
with dose escalation from 10  ^ -10^  ^ pfu. 20 patients had received previous 
radiotherapy and 8 had received prior chemotherapy. Patients were eligible 
for retreatment four weekly. Treatment was well tolerated with the main 
toxicity being mild Grade I/II flu-like symptoms and occasional discomfort 
at the injection site. Dose limiting toxicity was not reached at the highest
dose of 10^  ^ pfu. However, further dose escalation was not carried out 
because the maximum virus manufacturing capacity had been reached. In- 
situ hybridisation showed viral replication in 4 of 22 post-treatment biopsies 
all of which had mutant p53. However there was no statistically significant 
correlation between viral replication and p53 status. MRI scans were 
suggestive of central necrosis of injected tumours in 5 cases, 3 of whom 
were measured using non-conventional criteria as partial, and 2 as minor 
responses. A further 8 patients had stable disease in the injected tumours. 
The response duration for the 3 partial responses were 4, 8 and 12 weeks. 
Of the 5 patients showing a tumour response, 4 had mutant p53 on gene 
sequencing suggesting a selective response in p53 mutant tumours. However 
this was not statistically significant. Despite evidence of local response, in 
most cases progression of disease at uninjected sites eventually occurred. A 
multiple injection study was then carried out in 10 patients by 5 daily 
intratumoural injections. Toxicity was more frequent with 30% of patients 
reporting flu-like symptoms compared to 10% in the single injection 
protocol, but toxicity grade was not increased remaining at Grade I or II. 
There was improved viral distribution with 5 out of 7 tumours being positive 
for virus (3 patients did not have post-treatment biopsies done). However, 
only 1 of the 10 patients treated had a partial response though this was of 
longer duration than the single injection responses. To further evaluate the 
efficacy of a multiple injection protocol we are currently proceeding with a 
phase II study by multiple intratumoural injection in the same group of 
patients. In addition, recent work has shown additive cytotoxicity with virus 
combined with chemotherapy and radiotherapy (Heise et al,1997; Ganly et
10
al, unpublished results) and therefore a combination study with 
intratumoural virus and intravenous cisplatin/5FU is underway (Nemunaitis 
et al,1998).
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Chapter 1 
Introduction
1.1. GENERAL INTRODUCTION
Human adenoviruses have great potential as delivery vehicles for 
genes to treat many human diseases, including cancer (Ginsberg,1996; Ko et 
al,1996; Esandi et al,1997; Quillien et al,1997; Wilson ,1996). An 
alternative approach to cancer therapy involves the use of replication 
competent adenoviruses which can selectively replicate in and cause lysis of 
cells which lack wild type p53 function (Bischoff et al, 1996). The ElB 
attenuated adenovirus, Onyx-015, has an 800bp deletion in the E lB  region 
which codes for the 55kDa protein of ElB. The normal function of this 
protein is to bind to and inactivate the p53 protein in infected cells. Since 
Onyx-015 lacks this protein it is unable to replicate in cells with functional 
p53 since it cannot inactivate p53. However, it will replicate effectively in 
cells with non-functional p53 causing cytolysis (Figure 1). This approach 
has potential advantages over the traditional therapies of chemotherapy and 
radiotherapy because of the possibility of targeting tumours at a molecular 
level leaving normal tissue unaffected.
p53 is the most important tumour suppressor gene and plays an 
important role in the negative regulation of the cell cycle (Lane et al,1992). 
Its normal function is to recognise and respond to DNA damage induced by 
radiation and other cytotoxic agents, causing either a G1 arrest or apoptosis 
(Levine,1997 for review). p53 is the most commonly mutated gene in human 
cancer and is inactivated in over 50% of human tumours (Hollstein et al, 
1991). The incidence of p53 mutation in primary head and neck squamous 
cell cancer varies from 38% -53% ( Boyle et al,1993; Brachmann et al,1992; 
Koh et al,1998; Mao et al,1996; Olshan et al, 1997). In recurrent HNSCC the
14
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incidence may be even higher. The prognosis for patients with recurrent 
head and neck cancer is also very poor with average survival of between 3-6 
months and current treatment options including brachytherapy (Nickers et 
al,1997) and chemotherapy (Clavel et al,1994) yield only short lasting 
responses with no significant survival benefit (Forastiere et al,1994). There 
is therefore a great need for new forms of therapy for this disease. Therefore 
a therapy such as Onyx-015, which selectively destroys tumours with mutant 
p53, may be particularly useful in the treatment of recurrent head and neck 
cancer. The objectives of this thesis were therefore to determine by in-vitro 
and in-vivo studies whether squamous cell carcinoma of the head and neck 
would be a suitable target tissue for Onyx viral therapy and to carry out a 
phase I dose escalation trial using Onyx-015 in patients with recurrent p53(-) 
squamous cell cancer of the head and neck.
1.2. SQUAMOUS CELL CANCER OF THE HEAD AND NECK .
1.2.1. Epidemiology.
Squamous cell carcinoma of the head and neck includes cancer of 
the oral cavity, pharynx, larynx and paranasal sinuses. It is a cancer which 
has a high mortality and which causes significant morbidity with problems 
with speech, swallowing and pain control. It is the 6th most common cancer 
world-wide (Parkin et al, 1984). In the USA , 45,000 new cases of head and 
neck cancer are diagnosed each year, and 14,000 people die from the 
disease (Boring et al, 1993). In white men, the incidence is decreasing but in 
black men it is increasing (Miller et al, 1992).
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Epidemiological studies have shown a strong association with 
alcohol and tobacco abuse. Tobacco usage is the single most important 
aetiological factor and increases the risk of HNSCC by a factor of x5-25 
(Rothman et al,1980), Recently it has been shown that tobacco carcinogens 
can induce specific mutations in the p53 tumour suppressor gene with G to 
A transitions being the most frequent mutation (Brennan et al, 1995). In 
patients who continue to smoke, there is a high incidence of second primary 
tumours (10-30% of patients) with a 2-3% risk each year (Silverman et al, 
1983; Wynder et al , 1969). Smokeless tobacco (snuff) is also associated 
with the development of HNSCC due to the presence of carcinogens such as 
N-nitrosoamines, polonium-210 and benzopyrene (Hoffman et al, 1986). 
Alcohol increases the risk of HNSCC and there is a synergistic interaction 
with tobacco (Saracci et al, 1987). Dietary factors are also important and 
epidemiological and laboratory studies have shown that carotenoids 
(Vitamin A and synthetic retinoids) inhibit epithelial carcinogenesis. Studies 
have shown an inverse relationship with HNSCC formation and Vitamin A 
consumption (Mackerras et al,1988; Marshall et al, 1982). Chemoprevention 
trials with the synthetic retinoid 13-cis-retinoic acid have shown the 
effective inhibition of the development of second primary tumours ( Hong et 
al, 1990). Poor oral hygiene increases the risk of oral cancer by a factor of 
x3 (Graham et al, 1977). Occupational factors are small but important 
aetiological factors. Wood dust, exposure to organic compounds and coal 
products are important factors (Maier et al, 1991). Nickel and asbestos 
exposure are also related mainly in laryngeal cancer (Burch et al, 1981). 
There is also a small familial risk with an increased risk of HNSCC in first
16
degree relatives (Cloos et al, 1996; Foulkes et al, 1995; Foulkes et al, 1996). 
Heritable factors which increase genetic susceptibility include DNA repair 
capability ( Hsu et al, 1987), ability to metabolise carcinogens (Henderson et 
al,1998; Matthias et al,1998), altered oncogene and tumour suppressor gene 
function. DNA repair capability can be measured by a mutagen sensitivity 
test using bleomycin (Spitz et al, 1989; Schantz et al, 1990).
1.2.2. Classification and Staging of HNSCC.
Accurate staging in head and neck cancer is critical as it determines 
treatment modalities, survival and locoregional recurrence rate. The classical 
method of staging is the TNM classification system (Beahrs et al, 1988; 
Robbins,1991). This classification system is determined by direct 
visualisation of the tumour clinically or by endoscopy and palpation of the 
neck under a general anaesthetic, radiological visualisation by MRI, CT or 
U/S , and histological confirmation of cancer. T indicates the size, extent of 
invasion and site of invasion of the primary tumour. N describes the extent 
of cervical lymph node métastasés and is determined by the location and 
size of the nodes. M indicates the presence or absence of distant métastasés. 
For example, for oral cancer the TNM classification is as below:
TNM classification of oral cavitv cancer:
T T l=  <2cm.
T2= >2cm <4cm.
T3= >4cm.
T4= Extension to bone/muscle.
N N l= Ipsilateral single lymph node < 3cm
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N2= Ipsilateral single lymph node > 3cm but < 6cm or 
Ipsilateral multiple lymph nodes < 6cm or 
Bilateral,contralateral lymph nodes < 6cm 
N3= Lymph nodes > 6cm 
M Distant métastasés.
Metastatic spread to cervical lymph nodes is of poor prognosis since 
there is a 50% decrease in survival, increase in metastatic spread, and 
increase in locoregional recurrence (Snow et al, 1982). The presence of 
positive lymph nodes increases the chance of distant métastasés. Leemans et 
al, 1993 showed that if extranodal spread is present the incidence is 19.1% 
and if 3 or more nodes are positive the incidence of distant métastasés 
increases to 46.8%. Therefore in patients with 3 or more positive lymph 
nodes and/or extranodal spread there is an argument for adjuvent systemic 
therapy. Since the presence of positive nodes in the neck significantly affects 
the prognosis, the identification of clinically occult métastasés is critical for 
staging. Unfortunately, light microscopy frequently misses micrometastases 
since the detection rate is only 1 cancer cell in 20 normal cells. Recent 
advances in molecular biology have lead to the development of PCR 
methods which detect 1 cancer cell in 10,000 normal cells. Brennan et al, 
1995 used a molecular probe against mutant p53 to detect cancer cells in 
ceiwical lymph nodes. 21% of patients with negative nodes on light 
microscopy were positive by molecular probing resulting in a more 
advanced staging group in these patients. These molecular techniques give a
18
better prediction of survival, prognosis and a better determination of 
treatment modalities (Brennan et al, 1996).
1.2.3. Treatment of primary HNSCC.
Treatment of HNSCC depends on the stage of disease. Early stage 
disease is curative and consists of either surgical excision and reconstruction 
followed by adjuvant radiotherapy or radiotherapy alone. Late stage disease 
is considered noncurative and any treatment is for palliation. This may 
consist of external beam radiotherapy, local radiotherapy using radioactive 
implanted wires (Brachytherapy), systemic chemotherapy, surgery or a 
combination of these therapies.
The two most common and important causes of treatment failure are 
local recurrence and the development of second primaries. Only 10-15% of 
patients die of distant metastatic disease (Whitaker DC, 1987).
1.2.4. Recurrent disease.
a) Aetiology
There are many factors which predispose to the development of 
locoregional recurrence. The most important factor is incomplete surgical 
resection margins (Snow et al, 1989; Jones et al, 1992). This is determined 
not only by the experience of the surgeon but also by the site of the primary 
tumour which may limit the extent of surgical excision. For example, in 
larger tumours of the oropharynx and oral cavity it may be difficult to obtain 
adequate surgical resection margins and still preserve organ function. 
Recurrence in the neck is more likely if there are multiple nodes present and
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if there is extranodal spread of disease. As well as site and extent of surgical 
resection, recurrence is also determined by the dose and timing of adjuvent 
radiotherapy. Delays in radiotherapy treatment beyond 6 weeks post surgery 
and radiation doses less than 54 Gy have been shown to result in poorer 
survival and disease free intervals (Peters et al,1993). Other factors which 
predispose to recurrence include poor differentiation of the primary tumour 
and evidence of neurogenic and vessel invasion. Woolley et al,1992 also 
showed an increase risk of recurrence if blood transfusion was carried out at 
the time of primary surgery. Molecular markers are also important. 
Amplification of the oncogene Cyclin D1 has been associated with 
recurrence and shortened survival (Michalides et al,1995). Brachman et 
al,1992 has shown that patients with mutations in the tumour suppressor 
gene p53 have a shorter time to recurrence. Overexpression of p53 has been 
shown to correlate with an increased incidence of recurrence and the 
development of second primaries and hence reduced survival (Shin et 
al,1996). Antibodies to p53 have also been shown to be of prognostic 
significance (Werner et al,1997). In a prospective study of primary head and 
neck squamous cell cancer (HNSCC), patients with positive serum 
antibodies to p53 had an increased incidence of tumour recurrence , second 
primaries and tumour related deaths (44.7% in antibody positive group 
compared to 21.1% in antibody negative group).
The single most important factor which predisposes to recurrence is 
incomplete surgical margins (Snow et al, 1989; Jones et al, 1992). The best 
treatment for incomplete surgical margins is reoperation (Zieske et al, 1986) 
or radiotherapy if the morbidity from further surgery is too great. The
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detection of tumour cells at resection margins is by light microscopy. 
However, light microscopy only detects 1 cancer cell in 20 normal cells 
(5%) yet <1% of tumour cells in the total cell population is associated with 
recurrence. More sensitive methods are therefore required to detect tumour 
cells at resection margins. Recently Brennan et al, 1995 used a molecular 
probe against the patients mutant p53 to detect tumour cells at resection 
margins. A schematic diagram of this method is shown in Figure 2. Using 
this technique, 25 patients with negative margins on light microscopy were 
evaluated. 13 were positive by molecular probing and 12 were negative. All 
those that were negative had no recurrence at follow up. Of the 13 positive, 
5 developed recurrence and 8 did not. Moreover, the site of recurrence was 
at the site of positive tumour margin. As a consequence of this study a large 
multicenter trial has commenced examining the feasibility of this approach 
in the detection of incomplete resection margins. This is clearly important 
since these techniques would help to determine treatment. Patients with 
positive margins can be treated more aggressively by reoperation and 
adjuvant radiotherapy and closer follow up. Those with negative margins by 
molecular probing may not need adjuvant therapy thus reducing morbidity. 
At present these techniques are limited by cost and time but with advancing 
technology these will be overcome. 
b) Management
Improvements in surgical reconstruction due to the development of 
microvascular free tissue transfer, better radiotherapy protocols such as 
hyperfractionation and chemoradiation (Zidan et al,1997; Adelstein et 
al,1997; Koness et al,1997; Lavertu et al,1999) have led to improvements in
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locoregional control of head and neck cancer. As a result, more patients 
present with distant metastatic disease than before and therefore purely 
recurrent disease is less frequent. As a consequence, many clinical trials 
describing new treatments for recurrent head and neck cancer often include 
patients not only with locoregional recurrence but also with distant 
metastatic disease and locally advanced primary disease. Therefore when we 
discuss the management of recurrent disease it should be noted that many 
clinical trials include this mixed group of patients and this should be 
considered when interpreting any conclusions drawn from these clinical 
trials.
i) Surgery
Surgery plays a role in the treatment of both local and regional 
recurrence but only where curative surgery is possible or surgery results in 
significant palliation of symptoms. Recurrence in the neck can be treated 
surgically if the neck has not been previously treated either with surgery or 
radiotherapy. If a selective neck dissection has been carried out and 
recurrence has occurred outside the neck dissection field a complete radical 
neck dissection can be done in this case. However, usually the neck has 
already been treated with radiotherapy. In this case it is technically 
demanding to resect the tumour due to fixation of the tumour to local 
structures such as the carotid artery or vertebrae and it is also likely to be 
unsuccessful because of extranodal spread of disease. Surgical treatment of 
local recurrence is dependent on the site and previous treatment of the 
primary tumour. T1 and T2 tumours of the glottic larynx are treated with
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radiotherapy and recurrence in this situation can be treated with curative 
intent with either a partial laryngectomy (Kooper et al,1995; Nibu et 
al,1997) or total laryngectomy. Surgical salvage can also be carried out for 
supraglottic tumours though the chance for cure is less than for glottic 
tumours (Tu et al,1997). Recurrence in the oral cavity ( oral vestibule, 
buccal mucosa, gums, floor of mouth, oral tongue, hard palate, retromolar 
trigone) of small T1 and T2 tumours is difficult to detect early if the patient 
has had radiation treatment. However with close follow up these patients 
can be successfully salvaged surgically (Meyza et al,1991). With larger T3 
and T4 oral cavity tumours, primary surgery and radiotherapy often fail and 
further surgery is rarely possible nor curative. In the oropharynx (base of 
tongue, faucial arch, tonsillar pillars and fossa and posterior pharyngeal 
wall) recurrence can be treated surgically if it involves the tonsillar pillars or 
fossa. However recurrence of the base of tongue is rarely curative since 
these tumours are hard to detect and therefore present late. Radical surgery 
in the form of a total glossectomy and laryngectomy is often required but 
even with such surgery further recurrence often occurs within 1 year and 
long term survival is very poor.
ii) Reirradiation.
Surgery and adjuvant radiotherapy or radiotherapy alone are the main 
therapies for primary head and neck cancer. For recurrent disease, the main 
concern with reirradiation is damage to previously irradiated tissues such as 
the spinal cord, skin and salivary gland. External beam radiotherapy can be 
carried out but is best when the time interval from primary radiotherapy is 
greater then 12 months to reduce any potential toxicités. Local control of
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50% can be achieved if the radiation dose is greater than 60 Gy. 
Alternatively, lower doses of radiation can be given either with 
brachytherapy (Nickers et al, 1997; Harrison et al,1997) or by combining 
external beam radiotherapy with chemotherapy (chemoradiation).
Low dose radiotherapy in the form of brachytherapy has been shown 
to be effective in the treatment of primary head and neck cancer, especially 
in base of tongue tumours. However it also has a role in recurrent disease. 
Because the dose of radiation is lower (20-40Gy) and the depth of radiation 
penetration small, toxicity in previously irradiated tissue is limited. Nag et 
al,1996 have reported local control of 17% in patients using 1^ ^^  implanted 
wires. The dose of external beam radiotherapy can also be reduced by 
combining with systemic chemotherapy (chemoradiation). Haraf et al, 1996 
reported a 5 year survival of 22% and progression free survival of 26% 
using a combination of cisplatin/5FU/Hydroxyurea with radiotherapy 
(median dose 50Gy). Interstitial radiotherapy can also be combined with 
local tumour interstitial hyperthermia since hyperthermia kills hypoxic and 
S phase cells, neither of which are killed by radiation. Petrovic et al, 1989 
reported a complete response of 68% and partial response rate of 32% in 
sites treated by this technique. Recently it was reported that gemcitabine (an 
analogue of deoxycytidine) was a potent radiosensitizer (Shewach et 
al,1996). Using a low dose of gemcitabine 2 hours pre-radiotherapy, a phase 
I trial by Eisbruch et al,1997 in 8 patients gave a complete response in 7 
patients. However there was excessive mucosal and pharyngeal toxicity at 
the dose used and therefore studies using lower doses are planned.
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Hi) Chemotherapy
Chemotherapy may be given by systemic, intratumoural or 
intraarterial administration. Systemic chemotherapy may be given either as a 
single agent e.g. methotrexate or in combination e.g. Cisplatin/5FU. 
Treatment with combination chemotherapy increases overall response rates 
to 30-40% (Yokes,1996) compared with single agents where the response 
rate is only 10-20% (Jacobs et al,1992), but there is no improvement in 
survival (median survival is 6 months in both cases) ( Forastiere et al, 1994). 
In a randomised trial carried out by the EORTC (European Organisation for 
Research and Treatment of Cancer), 382 chemotherapy naive patients with 
recurrent or metastatic head and neck cancer were randomly assigned to 
either a combination of CABO (cisplatin, methotrexate, bleomycin, and 
vincristine), cisplatin and infusional 5 fiurouracil, or cisplatin alone (Clavel 
et al, 1994). Major responses were similar for CABO (34%) and cisplatin / 
5FU (31%) but better than cisplatin alone (15%). However, there was no 
difference in progression free survival and overall survival between the 3 
arms.
Intratumoural chemotherapy has been reported using a
cisplatin/epinephrine gel suspension. In a study by Burris et al,1996, 45 
patients had weekly intratumoural injection for 4 weeks. The response rate 
of treated tumours was good with 50% of tumours responding to therapy of 
which 40% were complete responses. However 50% of patients developed 
local toxicity with pain on injection, swelling, ulceration and reports of 
carotid artery blowouts and this has limited its use. However intratumoural 
electrochemotherapy (ECT) may provide improved responses with less local
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tissue toxicity. Electrochemotherapy involves the intratumoural injection of 
low dose cytotoxic (cisplatin, bleomycin) and then the application of an 
electric current via electrodes which penetrate the tumour (electroporation). 
Electroporation causes a transient increase in cell membrane permeability 
and allows larger molecules to penetrate the cell. In vivo studies have been 
encouraging for a wide range of tumour types including head and neck 
(Hasegawa et al,1998; Nanda et al,1998). Studies have also been carried out 
in head and neck cancer patients. Panje et al,1998 reported 5 complete 
responses and 3 partial responses in 10 patients treated by 
electrochemotherapy using a low dose of bleomycin.
Intraarterial chemotherapy has also been reported. In a phase I trial 
carried out by Robbins et al, 1994, major responses were 86% (41% CR) in 
22 untreated advanced stage patients and 62% (25% CR) in 16 recurrent 
disease patients.
Chemotherapy combined with biological agents such as interferon 
has been reported but with no beneficial effects (Benasso et al, 1993; 
Cascinu et al, 1994; Huber et al,1994 ). Benasso et al, 1993 treated 14 
patients with cisplatin/5FU and recombinant interferon alpha-2b with a 
major response rate of 54% (31%CR). However, Cascinu et al, 1994 treated 
34 recurrent or metastatic disease patients with a similar protocol with a 
major response rate of only 23%.
New chemotherapeutic agents are currently being evaluated. 
Docetaxel (a taxane) produced a response rate of 32% of median duration of 
6.5 months when given to 37 patients with recurrent or metastatic disease 
(Catimel et al, 1994). Paclitaxel has produced an overall response rate of
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40% in a phase II trial reported by Forastiere et al,1998. Interestingly 
response rates were increased to 67-77% when paclitaxel was combined 
with cisplatin (Schilling et al,1997; Hitt et al,1997). However when 
paclitaxel was combined with carboplatin (Fountzilas et al,1997) a response 
rate of only 23% was observed. These differences are presumably due to the 
differences in patients studied in respect to site of tumour and previous 
treatment. However, it is clear that paclitaxel has biological activity in head 
and neck cancer and has a role in the treatment of recurrent disease either as 
a single agent or in combination (Shin et al,1999).
Other new chemotherapeutic agents include the antimetabolite 
gemcitabine, an analogue of deoxycytidine. This has shown only 7 partial 
responses (13% response rate) in 54 patients with recurrent or metastatic 
disease (Catimel et al, 1994). However, when combined with Paclitaxel a 
response rate of 41% (11% CR and 30% PR) has recently been reported. 
Although this response rate is greater than combination therapy with 
cisplatin/5FU, the median time to progression of 4 months and median 
survival of 9 months are not significantly better than cisplatin/5FU therapy.
Other new agents include the antimetabolite thymetaq (Belani et 
al,1997), the Topoisomerase I inhibitor topotecan (Robert et al,1997) and 
Topoisomerase II inhibitor amonafide (Leaf et al,1997). Response rates from 
these agents have been poor at 14%, 14% and 3% respectively and it is 
unlikely that they will have any role in the treatment of recurrent disease.
Therefore, overall it is generally agreed that results of chemotherapy 
show only moderate response rates and these are of short duration producing 
little or no increase in survival. New chemotherapeutic agents have failed to
27
show any significant improvement in response with the possible exception 
of the taxanes. In addition, although different delivery systems in the form of 
intraarterial or intratumoural injection of chemotherapeutics have shown 
better responses, they are limited by their local tissue toxicity and also by the 
technical difficulty particularly in intraarterial administration.
iv) Biological therapies.
Biological therapies including immunotherapy and gene therapy 
have recently caused much interest. Such treatment has the potential to 
selectively target the tumour while leaving normal tissue relatively 
unaffected. These therapies are discussed in detail later (see 1.5. Gene 
therapy in head and neck cancer page 45).
1.2.5. Development of second primaries.
The other main cause of treatment failure is the development of 
second primaries in the aerodigestive tract including the oral cavity, lung 
and oesophagus. These are classified into synchronous (6 months from time 
of first primary) or metachronous (greater than 6 months). There are two 
current theories to the increased incidence of second malignancies. The first 
is the “field cancérisation theory” which is based on the hypothesis that the 
whole of the aerodigestive tract has been exposed to the same carcinogen 
(Slaughter et al, 1953). The second is the “common clonal origin theory” 
(Norwell,1976) in which all second and subsequent malignancies are 
believed to have developed from the same clone of malignant cells and these 
have proliferated to replace normal epithelium. There is evidence to support
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both of these theories ( Bedi et al,1996; Califano et al, 1996; Scholes et al, 
1998). The overall incidence of second primaries is 10-20% ( Schwartz et 
al, 1994; McGarry et al, 1992). However, the incidence varies with the site 
of the primary cancer. The 5 year second cancer incidence based on site of 
the primary cancer is 46% for base of tongue, 34% for pyriform sinus, 23% 
for larynx, 18% for oral cavity, 15% for tonsils and 10% for mobile tongue. 
The survival rate after the second cancer is also influenced by the site of the 
second cancer- the 5 year survival rate is 20% for second HNSCC, 3% for 
oesophageal cancer, 2% for lung cancer. Therefore the development of a 
second primary is almost always fatal. There is therefore a need for 
screening programs and chemoprevention trials in all HNSCC patients. 
Screening can be done by regular follow-up panendoscopy including 
laryngoscopy, bronchoscopy and oesophagoscopy. Chemoprevention of 
second cancers may be possible with retinoids (natural or synthetic 
derivatives of Vitamin A) since it has been reported that the synthetic 
retinoid 13-cis-retinoic acid (13cRA) can reverse oral premalignancy by 
inducing tumour cell differentiation and inhibiting proliferation (Braakhuis 
et al,1997). A clinical study by Benner SE et al, 1994 has also shown a 
reduced incidence of second primaries of 4% in those treated with 13cRA 
compared to 24% in untreated patients.
1.3. MOLECULAR GENETICS OF HEAD AND NECK CANCER
Head and neck carcinogenesis is a multistep process in which cells 
accumulate many genetic alterations followed by clonal expansion. These 
alterations include the activation of oncogenes and the inactivation of
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tumour suppressor genes. It is estimated that between 6 to 10 independent 
genetic events are required for cancer formation (Renan et al,1994). A 
model for head and neck carcinogenesis has recently been proposed by 
Califano and Sidransky,1996. This is shown in Figure 3.
1.3.1.Cytogenetics
Progression in head and neck carcinogenesis is associated with 
increasing aneuploidy with complex chromosome abnormalities and 
rearrangements. Chromosomal losses occur on chromosomes 3p, 5q, 8p, 9p, 
18q, 21q (Jin et al,1993; VanDyke,1994). Loss of 18q is associated with 
poor prognosis (VanDyke,1994) and loss of 3p21, 8 p ll, 14q are associated 
with reduced radiosensitivity (Cowan et al,1993). Areas of chromosomal 
gain or amplification occur at 3q, 5p, 7p, 8q and llq l3 .
1.3.2.Tumour suppressor genes and allelic losses.
Generally, point mutation of one suppressor allele is followed by 
deletion of the 2nd allele and thus total inactivation of tumour suppressor 
function. Thus, chromosomal deletions (allelic losses) are markers for 
tumour suppressor gene loci. The advent of microsatellite markers, which 
are small DNA repeat units highly conserved throughout the human genome, 
has allowed the mapping of areas of chromosomal deletions and the location 
of tumour suppressor gene loci. This is because these microsatellites are 
able to distinguish the maternal and paternal alleles in normal DNA. This 
pattern can then be compared with tumour DNA in which deletion is 
represented by a loss of either the maternal or paternal allele. Using
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microsatellite markers, allelotypes of head and neck cancer have now been 
reported (Nawroz et al, 1994; Ahsee et al,1994).
The most commonly deleted region (-66%) is on chromosome 9p21- 
22 which has been shown to harbour the tumour suppressor gene p i6 ( 
Serrano,1993). Allelic loss here occurs early and is present in early lesions 
such as dysplasias and carcinoma-in-situ (van der Riet,1994). Thus pl6 
inactivation is the first step in head and neck carcinogenesis. The 
mechanism of inactivation of p l6  is only rarely by point mutation (Cairns et 
al,1994) and more commonly by homozygous deletion or méthylation of the 
5’ CpG rich region of p l6  ( Merlo et al,1995; Herman et al,1995).
A 2nd commonly deleted locus is at chromosome 3p and again 
occurs early in head and neck carcinogenesis. Recently a new candidate 
tumour suppressor gene FHIT (fragile histidine triad) has been identified at 
3pl4.2 ( Mao et al,1996). Over 80% of HNSCC cell lines have 
abnormalities in at least 1 allele of the FHIT gene suggesting it has a role in 
HNSCC carcinogenesis (Virgilio et al, 1996).
High loss also occurs on chromosome 17p at the location of the p53 
tumour suppressor gene.This occurs after loss of 9p and 3p. Mutation of the 
p53 gene occurs in head and neck cancer in 38% -53% of patients (Boyle et 
al,1993; Brachmann et al,1992; Koh et al,1998; Mao et al,1996; Olshan et 
al,1997). Mutations are also found in premalignant lesions with a frequency 
of 33-35% ( el-Nagger et al,1995; Mao et al,1996) indicating that p53 
mutation occurs early in head and neck carcinogenesis and increases with 
tumour progression. Mutations are often G:T transversions located in exons 
7 and 8. Other sites include codons 149, 274, 288, 296, 298. The prevalence
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of mutations is also higher in patients who smoke tobacco or use alcohol 
chronically. The types of mutation in smokers is also different to non­
smokers/non-drinkers (Brennan et al, 1995).
Loss of 13q occurs in 60% of HNSCC patients. The retinoblastoma 
gene is located at this site but analysis by immunohistochemical staining of 
HNSCC tumours shows that inactivation of Rb occurs in only a small 
percentage of tumours (Yoo et al, 1994). This suggests that there is another 
tumour suppressor gene at 13q.
Losses also occur at 18q and this is associated with a reduced 
survival (Rowley et al, 1995). The highest incidence of LOH is at 18q21.1- 
21.3 using the microsatellite marker D18S35. 2 known tumour suppressor 
genes are located here - DCC and DPC4. However, these have not been 
shown to be implicated in HNSCC carcinogenesis ( Kim et al, 1996). Other 
genes in this area are being investigated.
1.3.3. Oncogenes.
Amplification of chromosome l lq l3  occurs in 30% of HNSCC 
patients. This is the location of the protooncogene Cyclin D1 ( Somers et al, 
1990). This amplification correlated with increased expression of the cyclin 
D1 gene (Jares et al, 1994). Moreover, DNA amplification of Cyclin D1 
correlates with progression in head and neck cancer (Jares et al, 1994; 
Callender et al, 1994). Overexpression is associated with early recurrence 
and shortened survival ( Michalides et al, 1995).
Mutations in the Ras oncogene occur rarely in HNSCC and thus Ras 
is not thought to be of importance in HNSCC carcinogenesis. The epidermal
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growth factor receptor is a receptor for extracellular growth factors TGFa 
and EGF. Binding of EGF to the receptor stimulates the growth of epithelial 
tissues. In HNSCC, amplification of EGER gene has been shown in cell 
culture and fresh tissues (Yamamoto et al,1986; Eisbruch et al,1987) and is 
higher in poorly differentiated compared to well differentiated tissues 
(Scambia et al, 1991). The c-erb-B2 oncoprotein is a 1851cDa 
transmembrane protein homologous to the EGF receptor. The gene is 
located on chromosome 17q21. In breast cancer it is amplified in 25-30% of 
cases and this is associated with early relapse and reduced survival. In 
HNSCC , erb-B2 expression is common but is not of prognostic significance 
( Craven et al, 1992; Field et al,1992). The myc gene family c-myc, 1-myc 
and n-myc are nuclear proteins important in cell proliferation and 
differentiation. Overexpression of c-myc prevents cell differentiation and 
increases cell proliferation. Overexpression of c-myc is present in 48% of 
HNSCC and is correlated with reduced survival (Field et al,1989).
1.3.4. Telomerase
The telomerase enzyme is associated with telomere elongation and 
cell immortalisation ( Rhyu et al,1995). It is activated in many human 
tumours and is undetectable in normal tissues ( Shay and Wright,1996 for 
review). In HNSCC, a study by Mao et al, 1996 showed telomerase 
expression in 90% of primary HNSCC and 100% of premalignant lesions 
such as dysplasias and hyperplasias. Normal epithelium showed no 
expression. Mutirangura et al, 1996 showed similar results.This suggested
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that telomerase activation occurs early in HNSCC and may play a role in 
early carcinogenesis.
1.3,5. HPV
Human papilloma virus (HPV) infection is important in the 
aetiology of HNSCC. The prevalence of HPV16 infection is 20-31% (Chiba 
et al, 1996). It has been shown that the E6 gene product of HPVI6 
inactivates the tumour suppressor gene p53 and promotes its degradation 
(Scheffner et al,1990). In addition, the E7 gene product inactivates another 
tumour suppressor, the retinoblastoma gene (Dyson et al,1989). Both of 
these events lead to increased cell proliferation and cellular transformation 
accounting for the role of HPV infection in head and neck carcinogenesis 
(Shindoh et al, 1995; Haraf et al,1996).
1.4. p 53 a n d  HUMAN CANCER.
1.4.1.Molecular Structure of p53.
a) Domains ofp53.
The p53 gene is located on chromosome 17p.21 and codes for a 393 
amino acid nuclear phosphoprotein. p53 was originally discovered as a 
protein complexed to SV40 T antigen in SV40 transformed cells (Lane and 
Crawford, 1979). Its structure can be divided into 3 domains - the 
transcriptional activation domain at the N terminus, the sequence specific 
DNA binding domain in the centre, and the oligomerisation domain at the C 
terminus. There are 5 conserved regions (conserved through evolution), 4 of 
which are located in the DNA binding domain (Figure 4).
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p53 is present predominantly as tetramers through the 
oligomerisation domain (Cho et al,1994; Jeffrey et al,1995). Dimers and 
monomers account for less than 5% of the total p53 molecules in a cell. The 
sequence specific DNA binding domain (Pavletich et al, 1993; Wang et 
al,1993) is very important as p53 regulates transcription through this region. 
p53 binds specifically to a p53 responsive element that contains repeats of 
the consensus binding sequence Pu-Pu-Pu-C-A/T-T/A-G-Py-Py-Py where 
Pu and Py are purine and pyrimidine nucleotides respectively (El-Deiry et 
al,1992).The N terminus of p53 is the transcriptional activation domain. 
This region can transcriptionally activate or repress other genes. p53 acts as 
a transcriptional activator of mdm2, box, IGF-BP3, p21,GADD45, Cyclin G, 
Thrombospondin (Dameron et al, 1994) and acts as a transcriptional 
repressor for the genes PCNA (Proliferating Cell Nuclear Antigen), c-fos ,c- 
jun, IL~6 and bcl2 (Horikoshi et al, 1995).
b) Phosphorylation ofp53.
p53 protein is extensively post-translationally modified, mostly by 
phosphorylation and this is important in regulation of p53 function 
(Meek,1994). p53 is phosphorylated at sites within its N terminal and C 
terminal regions by several protein kinases. One such kinase is the double 
stranded DNA dependent protein kinase, DNA-PK (Lees-Miller et al, 1990). 
It is a nuclear serine/threonine protein kinase. Activation of DNA-PK 
requires DNA double strand breaks or other discontinuities in DNA 
(Gottlieo et al,1993). DNA-PK phosphorylates human p53 at serines 15 and 
37 (Lees-Miller,1992). The DNA-PK phosphorylation sites are localised
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within the transcriptional activation domain of p53. These sites also interact 
with transcription factors such as the TAFs and cellular coactivators 
p300/CBP (Lill et al,1997). These phosphorylation sites are also located 
next to the region where p53 binds to mdm2 (Kussie et al,1996). Recently it 
was shown that DNA damage induces phosphorylation of p53 at serine 15 
via DNA-PK and that this results in the disruption of the p53/mdm2 
interaction (Shieh et al,1997) thus alleviating mdm2 inhibition of p53. 
Phosphorylation of serine 15 of p53 in response to DNA damage from 
ionising radiation has also recently been shown to occur by the ATM 
(Ataxia telangectasia) protein (Banin et al,1998; Canman et al,1998).
Relatively little is known about the enzymes which catalyse the 
dephosphorylation of p53 in vivo. However protein phosphatase 2A has 
been shown to dephosphorylate several phosphorylated sites on p53 in vitro 
( Scheidmann, et al 1991).
1.4.2. Activation of p53.
p53 is activated by DNA damaging agents such as ionising radiation 
and cytotoxics, hypoxia and UV light (Kastan et al,1991). DNA damage 
from ionising radiation causes p53 protein levels to rise in cells with an 
increase in transcriptional activity (Kastan et al,1992; Kuerbitz et al, 1992). 
Ionising radiation causes DNA damage by causing strand breaks in the DNA 
and these strand breaks signal p53 activation (Hartwell et al, 1989). It has 
been suggested that as little as one double strand break per cell can initiate 
the p53 pathway (Huang et al 1996). It has recently been shown that 
activation of p53 in response to DNA damage involves phosphorylation of
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p53 at serine 15 causing a conformational change in p53. This 
phosphorylation involves kinases including DNAPK (Shieh et al,1997) and 
ATM (Banin et al,1998; Canman et al,1998) as described above.
Exposure of cells to hypoxic conditions results in increased p53 
protein levels and can lead to p53 dependent apoptosis (Graeber et al, 1996). 
It is widely believed that this induction of p53 occurs in the absence of DNA 
strand breaks. It has been shown that depletion of ribonucleotide 
triphosphates (rNTP) using inhibitors of purine and pyrimidine biosynthesis, 
is sufficient to induce p53 and p53 dependent G1 arrest (Linke, et al 1996). 
It may be the case that an inadequate supply of rNTPs results in changes in 
the RNA macromolecule population, analogous to the way that dNTP 
inhibitors lead to DNA strand beaks.
1.4.3. Normal function of p53.
p53 is the most important tumour suppressor gene and plays a central 
role in the negative regulation of the cell cycle (Lane,1992; Levine,1997 for 
review). In response to DNA damage or foreign DNA synthesis, wild type 
p53 is stimulated causing either a G1 arrest or apoptosis of the cells. 
Figure 5 shows a schematic diagram of p53 activation and p53 dependent 
G1 arrest and apoptosis.
a) G1 arrest.
Ionising radiation induced DNA damage can result in a G1 arrest 
which is mediated mainly by the p21 protein (El-Diery et al, 1993; Harper 
el al 1993). p21 mRNA levels, as well as protein levels, increase following 
exposure of cells to ionising radiation in a p53 dependent manner (Xiong et
37
cI
\
c*.73
o
Cu-3
C
&
r*-.ir.
c .
"3
C
r^ .iT,
c .
73
r i
II
al, 1993). p21 causes a G1 arrest by acting as a cyclin dependent kinase 
inhibitor preventing the phosphorylation of the Retinoblastoma gene product 
(pRb). In addition, p21 causes G1 arrest by inhibiting PCNA (proliferating 
cell nuclear antigen), a 36kDa protein capable of interacting with DNA 
polymerase a  and which normally stimulates DNA replication and repair 
(Luo et al, 1995 ). The binding of p21 to PCNA does not affect the DNA 
repair activity of PCNA but is thought to alter the availability of PCNA for 
DNA replication. p21 is the most important mediator of p53 dependent cell 
cycle arrest. However other genes transcriptionally activated by p53 may 
play a role in DNA damage arrest. These include Cyclin G (Okamoto et al, 
1996) and GADD45 (Kastan et al, 1992). Like p21, GADD45 also contains 
a p53 binding site and has been shown to be induced by p53 (Lu et al, 
1993).
b)Apoptosis.
Apoptosis, or programmed cell death, is the process by which a cell 
actively commits suicide under a tightly controlled cascade of events. 
Apoptosis is recognisable microscopically by characteristic condensed 
basophilic cytoplasm, darkly staining nuclei, and the presence of apoptotic 
cell bodies. DNA from cells undergoing apoptosis is cleaved into fragments 
of roughly 200 base pairs. The signals that trigger apoptosis include the 
presence of DNA damage, growth factor or nutrient withdrawal, disruption 
of cell matrix interactions, altered expression of potent cellular oncogenes 
such as myc, and viral infection.
Apoptosis is controlled by the Bcl2 group of proteins which include 
the apoptotic factors bax (Oltavi et al 1993), bak and bclxg (Boise et al,
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1993) and the antiapoptotic (survival) factors Bcl2, bad and bclxL, Bcl2 
protein is an intracellular membrane protein that resides in the outer 
mitochondrial membrane, nuclear envelope and parts of the endoplasmic 
reticulum. The protein has been shown to block cell death induced by
numerous stimuli including growth factor deprivation, Ca^^ ionophores, 
reactive oxygen species, some viruses, heat shock, and irradiation 
(Reviewed in White 1997).
p53 can transactivate bax (Selvakumaran et al, 1994) which contrasts 
with its ability to repress transcription of Bcl2 (Miyashita et al, 1994). Thus 
in response to DNA damage, p53 is activated causing activation of bax and 
repression of Bcl2. It has been proposed that when Bcl2 is in excess, Bcl2 
homodimers predominate and cells are protected and when bax is in excess, 
bax homodimers predominate and cells are susceptible to apoptosis (Oltavi 
et al, 1993) (Figure 6)
Although bax is the main mediator of apoptosis, the insulin-like 
growth factor binding protein 3 gene (IGF-BP3) may also be important in 
apoptosis (Buckbinder et al, 1995). IGF-BP3 protein has the ability to 
inhibit the signalling of insulin- like growth factor receptors and so plays an 
anti-raitogenic role in the cell. It can cause both G1 arrest and also 
apoptosis.
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1.4.4. Regulation and stabilisation of p53.
p53 levels are controlled by the protein mdm2 (Barak et al, 1993). 
This protein has the ability to complex with p53 and inhibit its 
transcriptional activity. Mdm2 is transcriptionally activated by wild type p53 
in response to DNA damage. Thus an auto-regulatory feedback loop exists 
between mdm2 and p53. Overexpression of mdm2 inhibits p53 dependent 
G1 arrest in response to irradiation (Barak et al, 1993; Perry et al, 1993). It 
was been shown that mdm2 also promotes the degradation of p53. This is 
thought to be an important mechanism in ensuring that the p53 signal is 
quicldy terminated (Haupt, et al 1997). It has been suggested that mutant 
p53 proteins have a longer half-life than wild type because they are not 
degraded by mdm2 (Midgley et al,1997). This is because mutant p53 is 
non-functional and is therefore not capable of activating mdm2 mediated 
degradation.
In response to DNA damage, p53 levels increase leading to 
increased transcription of mdm2. The auto-regulatory feedback loop 
between mdm2 and p53 would then lead to the early degradation of p53 and 
loss of p53 transcriptional activity. This is undesirable in a situation of DNA 
damage where prolongation of p53 transcriptional activity is required. Shieh 
et al,1997 recently showed that after DNA damage, N terminal 
phosphorylation of p53 occurs by DNA-PK at serine 15 and this disrupts the 
p53/mdm2 interaction. Thus p53 is stabilised and transcriptional activity is 
prolonged.
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Another factor, pl9^^-INK4a, has been reported to promote mdm2 
degradation and therefore stabilise p53 (Zhang et al,1998; Pomerantz et 
al,1998), This mechanism of regulating p53 activity is distinct from that 
involving DNA damage since no phosphorylation of p53 occurs. It has been 
shown that oncogenes such as the adenoviral E lA  and Myc regulate p53 
dependent apoptosis by the induction of pl9^^^ (Zindy et al,1998; de 
Stanchina et al, 1998). A schematic diagram showing the regulation of p53 is 
shown below.
Oncogenes DMA damage
(ElA  Myc) (IR,UV,drugs)
Kmases(DNA PK, ATIVI)
p53
Cell cycle arrest 
or apoptosis
1.4.5. Mutation of p53.
The most common somatic mutations in p53 are single base 
substitutions (point mutations) in the conserved regions of the gene i.e. 
exons 5-8 (Hollstein et al, 1991) (Figure 4). Most point mutations result in 
missense mutations which cause a change in a single amino acid. However a 
few result in frameshifts and premature termination of translation (Stop 
codons). These mutations are termed nonsense mutations. As well as single 
base substitutions, complete or partial deletions can also occur but these are 
not common. As a consequence of mutation, mutated p53 cannot bind or
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regulate transcription through the specific DNA binding sequence. Therefore 
cells which sustain DNA damage are unable to respond by p53 mediated G1 
arrest or apoptosis. Damaged DNA is retained leading to cellular 
transformation, genomic instability (Smith et al,1995) and the malignant 
phenotype. Germline mutations in p53 can also occur. Li-Fraumeni 
syndrome (LFS) is a rare autosomal dominant condition (Malkin et al,1990) 
in which patients are born with 1 mutated p53 allele and 1 wild type p53 
allele. Mutation of the normal allele by somatic mutation results in p53 
inactivation.These patients develop sarcomas in childhood (bone, soft 
tissues) and more rarely brain, lung, adrenocortical and bone marrow 
tumours.
1.4.6. Inactivation of p53.
As well as mutation and deletions, p53 may be inactivated by 
binding to cellular or viral proteins. The cellular factor mdm2 inhibits the 
transcriptional activity of p53 as previously described. Amplification or 
overexpression of mdm2 can therefore cause p53 inactivation mimicking 
p53 mutation. The mdm2 gene is frequently amplified in sarcomas (Oliner et 
al, 1992). Viral oncoproteins can also inactivate p53. Adenoviral E lB  
(551cDa) (Kao et al, 1990; Debbas et al, 1993; Sarnow et al, 1982) , HP Y E6 
(Lechner et al, 1992; Scheffner et al, 1990), and SV40 large T antigen 
(Gannon et al, 1987) ail bind to p53 causing inactivation of the p53 protein. 
The same viruses also inactivate the other tumour suppressor gene Rb 
(retinoblastoma) by other proteins adenoviral E lA  (Levine et al,1990), HPV 
E7 (Dyson et al,1989) and SV40 large T (Levine et al,1990).
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1.4.7. p53 abnormalities in HNSCC.
a) p53 overexpression
p53 overexpression occurs in 60-68% of primary HNSCC (Watling 
et al,1992; Field et al,1991). Field et al, 1993 showed that overexpression 
correlated with smoking. p53 overexpression also correlates with an 
increased incidence of recurrence and the development of second primaries 
and hence reduced survival (Shin et al, 1996). Sauter et al, 1994 showed that 
over 50% of preinvasive lesions overexpress p53 suggesting that p53 
overexpression is an early event and a marker for preinvasive lesions.
b) p53 inactivation
The p53 gene is frequently inactivated in HNSCC either by mutation, 
deletion or inactivation (by cellular factors mdm2 or viral factors 
HPVE6,E1B and SV40 proteins). The frequency of p53 mutations in 
primary HNSCC is 38% -53% ( Boyle et al,1993; Brachmann et al,1992; 
Koh et al,1998; Mao et al,1996; Olshan et al,1997) and increases with 
progression. Tobacco carcinogens induce p53 gene mutations (Brennan et al, 
1995; Lazarus et al,1996) and protein overexpression. Overexpression and 
mutation probably act at an early stage of squamous cell carcinogenesis 
(Shin et al, 1994; Sauter et al, 1995).
Brachman et al,1992 showed those patients with p53 mutations have 
shorter time to recurrence. In tumours with wild type p53, the p53 protein 
may be inactivated by HPVE6 and targeted for degradation by the ubiquitin 
degradation pathway. Brachman et al,1992 showed a 10% incidence of HPV
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in primary HNSCC as determined by PCR and all were in tumours with wild 
type p53.
In recurrent disease the incidence of mutation is predicted to be 
higher. This is one reason why treatment with a selectively replicating E lB  
adenovirus which targets mutant p53 tumour cells may be worthwhile in 
recurrent disease.
c) p53 serum antibodies.
Antibodies to p53 have been shown to be of prognostic significance 
(Werner et al,1997). In a prospective study of primary HNSCC, patients 
with positive serum antibodies to p53 had an increased incidence of tumour 
recurrence, second primaries and tumour related deaths (44.7% in antibody 
positive group compared to 21.1% in antibody negative group).
1.4.8. Clinical importance of p53 inactivation.
p53 dependent apoptosis is one of the main mechanisms of cell death 
by many cytotoxic agents. Thus loss of p53 function results in reduced 
sensitivity to chemotherapy (Lowe et al,1993; Lowe et al,1994; Eliopoulos 
et al,1995) and radiotherapy (Lowe and Schmitt,1993). p53 inactivation is 
also correlated with poor prognosis and disease progression (Lowe et 
al,1994). Therefore p53 inactivation is very important clinically. Because of 
this, new agents which either restore p53 function or which selectively target 
cells which lack p53 are being developed. Such genetic based therapy 
represents an area which is rapidly expanding in cancer therapy.
1.5. GENE THERAPY IN HEAD AND NECK CANCER.
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Treatment failure in head and neck cancer is predominantly from 
local or distant relapse following primary treatment or from the development 
of second primaries. In stage III or IV disease, which represents two thirds 
of patients presenting with head and neck cancer, locoregional recurrence 
occurs in 50-60% of cases and distant metastatic disease occurs in 25% of 
cases (Stupp et al,1994). Distant métastasés is most frequent in the lung 
followed by bone, liver, skin and brain (Merino et al,1977). Locoregional 
recurrence is usually treated with reirradiation, brachy therapy or 
chemotherapy whereas distant metastatic disease is treated with 
chemotherapy. In both cases only 35% of patients show any response to 
therapy and this is usually of short duration lasting 6-9 months (Forastiere et 
al,1994). Because of this poor response to current therapy, there has been 
much interest in the development of new therapies such as gene therapy 
(Breau et al,1996) since these therapies have the potential to specifically 
target tumour tissue leaving normal tissue relatively unaffected thus limiting 
local and systemic toxicity. As well as treating recurrent disease, these forms 
of therapy may also be useful in the treatment of minimal residual disease, 
either by local injection of surgical resection margins and the surgical bed to 
Idll local residual disease, or by systemic therapy to treat microscopic 
deposits of tumour at distant sites.
1.5.1. Principles of gene therapy.
Gene therapy involves the introduction of foreign DNA into somatic 
cells to produce a therapeutic effect (Fujiwara and Roth,1994 for review). 
The therapeutic gene is transferred into the tumour cells using a vector.
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Transfer may either be in-vivo in which the DNA and vector are directly 
introduced into the body, or ex-vivo in which cells are removed from the 
body, transfected with DNA and then reintroduced into the patient.
1.5.2. Gene delivery systems.
The mode of gene transfer can be classified into chemical, physical 
and viral. In chemical transfection DNA is introduced into cells using 
calcium phosphate, liposomes or DNA/protein complexes. Although useful 
for laboratory transfections, these are inefficient in vivo due to their poor 
efficiency of transfection. In addition, liposomes and protein DNA 
complexes are rapidly cleared from the body via the immune system. 
Physical methods of DNA transfection are by electroporation, 
microinjection and the use of ballistic particles. Electroporation guns for the 
introduction of chemotherapeutics as well as genes are currently being tested 
in various cancers including head and neck. In addition guns which fire 
small gold particles coated with DNA have recently been developed and are 
being tested. However, the most important method of transfer of DNA 
currently being used is viral vectors. Viruses used include retroviruses, 
adenoviruses, adeno-associated viruses and herpes viruses. Retroviruses 
contain RNA genomes that are reverse transcribed after introduction to 
produce a double stranded cDNA. This integrates stably and heritably into 
random sites of the host genome. These viruses give a high efficiency of 
transfer. The host range of cells which they infect includes fibroblasts, 
epithelial cells and smooth muscle cells. Cells of lymphoid origin are more 
resistant. They give permanent gene expression which is advantageous when
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we require long term expression of the transgene such as in cystic fibrosis. 
They are currently limited due to the low production titre that can be 
produced pfu) which reduces transduction efficiency into solid
tumours. Other disadvantages are that they only infect dividing cells, and 
that the stable random integration into the host genome may be dangerous if 
germ cell transfection occurs. They are also limited in the size of transgene 
which can be inserted (~7-8kb). Therefore, the use of retroviruses has 
recently been superseded by the use of adenoviral vectors (Wilson et 
al,1996; Ginsberg,1996).
Adenoviruses are double stranded DNA viruses. They can be made 
replication defective with deletion of the E l and E3 regions of their genome. 
The transgene can then be introduced into the vacated site. Adenoviruses 
currently used can carry approximately 6-8kb of DNA. However because 
they have a larger genome than retroviruses they can potentially carry larger 
transgenes up to 36 kb DNA in size. They have a tropism for a broader 
range of cell types and because they can be produced at high titres, -lO^^pfu 
, they have a higher transduction efficiency. Another advantage is that they 
can infect both nondividing as well as dividing cells. There is no integration 
into the host cell genome and therefore only transient gene expression 
occurs. This is adequate for cancer therapy but would not be desired in 
situations where long term gene expression is required such as cystic 
fibrosis. Gene expression using adenoviruses usually lasts for 7-42 days. 
Other disadvantages are that they continue to express other viral gene 
products which are recognised by the immune system leading to an 
inflammatory response and short term gene expression, they may become
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replication competent by genetic recombination, and because 90% of 
humans have antibodies to human adenoviruses pre-existing immunity may 
reduce the transduction efficiency to very low levels particularly on second 
exposure to the adenoviral vector.
1.5.3. Classification of cancer gene therapy.
There are four main types of genes which can be introduced into 
tumour cells:
1. genes which suppress the expression of an oncogene i.e. anti-oncogenes.
2. genes which restore a defective tumour suppressor gene(replacement gene 
therapy).
3. genes which enhance immune surveillance( immunotherapy)
4. genes which activate pro drugs into active chemotherapeutic agents(gene 
directed enzyme prodrug therapy i.e. GDEPT).
In head and neck cancer these therapies may be potentially useful in 
three clinical situations. Firstly, they may be useful for the treatment of 
locoregional recurrence by direct tumour injection or the treatment of distant 
disease by systemic therapy. Secondly, they may be used for the treatment of 
minimal residual disease by direct injection of the surgical resection bed and 
resection margins in order to prevent locoregional recurrence. Thirdly, they 
may be useful for the treatment of distant minimal residual disease by 
systemic therapy to target radiologically undetectable metastatic disease.
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Figure 7. Examples of gene replacement therapy (7a), immunotherapy (7b) 
and GDEPT (7c) in HNSCC.
1.5.4. Current tumour suppressor gene replacement therapies in 
HNSCC.
There is currently one approved trial for squamous cell cancer of the 
head and neck. This utilises a replication deficient adenovirus for the 
transmission and overexpression of a wild type p53 gene (daym an et 
al,1998). The hypothesis behind this is that the wild type p53 gene would be 
dominant over its mutant gene and select against proliferation and induce a 
p53 mediated apoptosis. In-vitro and in-vivo studies using such a technique 
have demonstrated growth suppression ( Liu et al ,1994, Liu et al ,1995; 
daym an et al, 1995). Phase I/II trials are underway at the MD Anderson 
Cancer Center, Texas, USA in patients with advanced local or regional 
cancer that is unresectable. Treatment is by direct intratumoural injection 
and is illustrated in Figure 7a. Results from the phase I trial showed no 
toxicity and evidence of tumour regression was found in some patients 
(daym an et al, 1998). Analysis of tumour biopsies showed expression of 
the p53 transgene and evidence of apoptosis was also detectable. Another 
tumour suppressor gene that could be replaced is p l6  since in HNSCC there 
is a very high frequency of p l6  inactivation either by mutation, deletion or 
méthylation (Reed et al,1996). It is believed to be one of the first steps in 
head and neck carcinogenesis and therefore would be a ideal target for gene 
replacement therapy. In-vitro and in-vivo studies using an adenoviral vector 
with a pl6 transgene are encouraging (Rocco et al,1998) and a phase I trial 
using this system is due to commence in patients with recurrent HNSCC at 
the Johns Hopkins Hospital, USA.
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1.5.5. Immunotherapy in HNSCC.
In immunotherapy, the aim is to either increase the immunogenicity 
of the tumour (Townsend et al, 1993) or increase the effectiveness of tumour 
infiltrating lymphocytes (Rosenberg et al, 1991). Non-specific 
immunostimulants (such as BCG, levamisole (an antihelminthic imidazole) 
and OK-432 (an inactivated low virulence strain of Streptococcus 
pyogenes), can be used to stimulate cytotoxic T lymphocytes. Both BCG 
(Taylor et al,1979) and levamisole (Olivari et al,1979) have failed to show 
any tumour response. However OK-432 has been reported to cause tumour 
reduction in some cases (Kitahara et al,1996). The immunogenicity of the 
tumour can be increased by transfecting into the tumour cells MHC class I 
and II genes to increase antigen presentation (Plautz et al,1993). Nabel et 
al,1993 have reported reduction of tumour size in a melanoma patient after 
gene transfer of MHC class I gene. The presence of antigen and MHC alone 
are insufficient for immune induction, and a class of molecules called 
costimulatory molecules are also required. These are expressed on antigen 
presenting cells and the best studied are called B7.1 and B7.2. Transfection 
of B7 into tumour cells should provide the necessary costimulation required 
for immune stimulation in immunogenic tumours and Chen et al,1994 have 
shown that B7 transduction into immunogenic lymphoma and melanoma 
cell lines using a retroviral vector decreased their tumourgenicity and 
induced protective immunity. Lang et al,1999 have shown that there is 
impairment of T cell activation in head and neck cancer patients and this is 
partly due to lack of B7.1 expression. They also showed that transduction of
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the B7.1 gene into head and neck cell lines resulted in T cell activation. 
Thus gene therapy using the B7.1 gene as the transgene may be a potentially 
useful method for immunogenic therapy in head and neck cancer patients. 
Gleich et al,1998 recently reported a phase I study using Allovectin-7 (i.e. 
B7 gene complexed to a cationic lipid) by direct intratumoural injection in 
patients with advanced head and neck cancer who did not express HLA-B7. 
This study showed no toxicity and a partial response to therapy in 4 out of 9 
patients treated. HLA-B7 expression was detected in 2 of the 9 patients and 
there was extensive apoptosis in both these patients.
The effectiveness of tumour infiltrating lymphocytes can be 
improved by cytokines interleukins 2 and 4 (Lin et al,1993), tumour necrosis 
factor, interferon alpha and gamma, and granulocyte-macrophage colony 
stimulating factor. These cytokines can stimulate the production of both 
tumour infiltrating lymphocytes and lymphokine activated killer cells in- 
vitro and these expanded cells are then used in adoptive immunotherapy ( 
Whiteside et al,1996; Boscia et al,1988; Sacchi et al,1990) (Figure 7b). 
Alternatively interleukin 2 can be injected directly into the patient either 
peritumourally (Whiteside et al,1993) or perilymphatically (Cortesina et 
al,1988). However, although immune activation is seen, responses have 
been very poor.
1.5.6. GDEPT in HNSCC.
GDEPT involves the introduction of a gene coding for an enzyme 
capable of activating an inactive prodrug into an active cytotoxic drug. The 
most common system used is the herpes simplex virus thymidine
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kinase/ganciclovir system. Herpes simplex virus thymidine kinase renders 
cells sensitive to the nucleoside analogue ganciclovir by converting 
ganciclovir into an active phosphorylated compound that terminates DNA 
synthesis. Since cancer cells divide more rapidly than normal cells, this 
treatment selectively kills tumour cells transduced with the gene rather than 
normal cells. The antitumour effect is dependent upon a biochemical 
bystander effect which is mediated by gap junctions between cells (Elshami 
et al,1996). The toxic metabolite is able to pass from a transduced cell into a 
nontransduced cell via gap junctions. Therefore only 10-20% of tumour cell 
transduction is required for efficacy. Selectivity can be achieved if the tk 
gene is linked to a tissue or tumour specific promoter. Adenovirus mediated 
gene transfer of the herpes simplex virus thymidine kinase gene has shown a 
reduced growth of squamous cell cancer in a nude mouse model (O’Malley 
et al, 1995; O’Malley et al, 1993) and a phase I clinical trial is currently 
underway at the Johns Hopkins hospital, USA (Figure 7c).
1.6. REPLICATING VIRUSES AS ANTICANCER AGENTS.
Despite bystander effects, the main disadvantage of current gene 
therapy vectors is the poor tumour transduction. One method to overcome 
this is to use a vector which is a replication competent virus which 
selectively replicates in tumour but not normal tissues. The tumour specific 
replication would increase the number of cells infected with virus and 
therefore deliver more therapeutic gene to the tumour. In addition, a 
replicating virus itself would cause lysis of any tumour cells infected. 
Recently, replication competent parvoviruses (Berns,1990; Rommelaere et
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al, 1991) and herpes simplex (Yazaki et al, 1995; Mineta et al, 1995) 
viruses have been used to achieve viral oncolysis. Parvovirus has the 
advantage that it infects a wide range of tissue types but are non-pathogenic 
in humans. Thus viral toxicity is limited. Attenuated herpes simplex viruses 
have been used for the treatment of brain neoplasms in in-vivo mouse 
models (Yazaki et al, 1995; Mineta et al, 1995) and human trials are 
underway (Rampling et al,1998). These replicate only in dividing tumour 
cells leaving normal brain tissue unaffected. No studies have been reported 
in head and neck cancer to date.
The use of adenoviruses in the treatment of cancer was described by 
Smith et al,1956 where tumour necrosis was shown by direct intratumoural 
injection in patients with ceiwical cancer. Recently there has been much 
research in developing adenoviruses which selectively replicate in and 
destroy tumours. Two main strategies have been developed. In the first 
strategy the adenoviral E lA  gene promotor is replaced by a tumour specific 
promotor. Rodriguez et al,1997 developed an adenovirus with the promotor 
for prostate specific antigen (PSA) to selectively replicate in prostate 
cancers, whereas Hallenbeck et al,1999 has developed a similar virus with 
the alpha feto protein (AEP) promotor to replicate in hepatocellular cancers. 
The second strategy is to remove the adenoviral genes whose normal 
function is to inactivate genes regulating the cell cycle i.e p53 and Rb. For 
example, deletion of the E lA  gene results in an adenovirus which replicates 
selectively in cells with no functional retinoblastoma (Rb) gene. Such a 
virus has shown efficacy in vivo in a glioma model (Fueyo et al,2000). 
Alternatively, deletion of the E lB  55kDa adenoviral gene may result in a
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virus which selectively replicates in cells with non functional p53. Indeed, 
the E lB  55kDa deleted adenovirus, Onyx-015, has recently been shown to 
selectively replicate in and lyse tumour cells with non functional p53 both 
in-vitro and in-vivo (Bischoff et al,1996; Heise et al, 1997). The E lB  55kDa 
protein binds directly to the N terminus of the p53 tumour suppressor gene 
and causes transcriptional inactivation of p53 ( Dobner and Shenk et 
al,1996; Teodoro et al,1997). In addition, E lB  55kDa also mediates the 
degradation of p53. This degradation of p53 is believed to be mediated by 
complex formation between p53, E lB  and E40RF6 (Dobner and Shenk 
,1996; Steeganga et al,1997) which targets p53 for degradation via the 
ubiquitin degradation pathway. Since Onyx-015 lacks this protein it is 
unable to replicate in cells with functional p53 since it cannot inactivate p53. 
However, it will replicate effectively in cells with non-functional p53 
causing cytolysis (Figure 1). In squamous cell cancer of the head and neck 
there is a high incidence of p53 abnormalities and therefore an E lB  deleted 
adenovirus, such as Onyx-015, may be potentially useful to treat this 
disease.
1.7. AIMS OF RESEARCH STUDY.
The aims of this research study were :
1. To determine whether Onyx-015 would selectively replicate in and lyse 
head and neck cell lines with non-functional p53.
2. To determine if Onyx-015 had efficacy in-vivo in human head and neck 
tumour xenografts in nude mice.
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3. To determine the incidence of p53 mutations and p53 inactivation in 
recurrent head and neck tumours.
4. To carry out a phase I dose escalation trial of an intratumoural injection 
of Onyx-015 in patients with recurrent p53(-) tumours of the head and neck.
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Chapter 2
Materials and Methods
2.1 MATERIALS
2.1.1 Chemicals
All chemicals were of AnalaR grade and were obtained from BDH 
Chemicals Ltd, Poole, Dorset or Sigma Chemicals. Ltd, Poole, Dorset 
except those obtained from the suppliers listed below.
Advanced Protein Products 
Foetal calf serum 
Beatson Institute Central Services 
sterile PBS (Phosphate buffered saline)
PE (PBS and EDTA)
Biogenex
Universal blocking solution 
J.BurroughlFADf Ltd. Witham, Essex 
ethanol
ENZQ Diagnostics Inc. Farmingdale. NY
Biotinylated adenovirus DNA probe
EMC, Rockland. ME
Nuseive agarose
Gatewav pic, Glasgow
Marvel dried non-fat milk powder
Gibco Europe, Life Technologies Ltd. Paisley
10 X DMEM
10 X RPMI
200mM glutamine
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2.5% trypsin 
penicillin 
streptomycin 
RNA ladder 
DNA ladders 
Fromega, Madison,WI 
Taq DNA polymerase 
dNTPs
Rathburn Chemicals Ltd, Walkerburn. Peebleshire 
phenol (water saturated)
Sigma Chemical Co.Ltd, Poole, Dorset
agarose
Tween 20
ethidium bromide
P~ mercaptoethanol
orange G
bromophenol blue
xylene cyanol
proteinase K
Rnase
Pepsin
Propidium iodide
Vector Laboratories Inc. Burlington.USA 
Yectashield antifade mounting medium 
BCIP/NBT substate
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DAB substrate 
Nuclear fast red 
ABC Mouse peroxidase kit 
ABC Rabbit peroxidase kit
2.1.2. Equipment and plasticware
Applied Biosvstems Ltd 
PCR reaction tubes (thin walled)
Becton Dickinson Labware. Plymouth, Devon 
tissue culture dishes (90mm,60mm)
Eastman Kodak Co, Rochester. New York 
Ektachrome colour slide film 
Fuii Photo Co.Ltd. Japan 
x-ray film
Gibco Europe, Life Technologies Ltd. Paisley
Nunc 1ml cryotubes
Nunc 8-well chamber slides (permanox)
Nunc 25cm^, 75cm^, 175cm^ tissue culture flasks 
Griener Labortechnik Ltd. Durslev 
eppendorf tubes
Hvbaid Ltd. Teddington, Middlesex 
Omnislide in situ system 
Labsvstems. Basingstoke 
pipette tips
Molecular Bioproducts. San Diego. CA
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aerosol- resistant tips
Pharmacia Ltd. Milton Keynes, Buckinghamshire 
Spin columns
Whatman International Ltd, Maidstone 
3MM paper
2.1.3. Antibodies
Oncogene Science
p53 DO-l(mouse monoclonal)
Sigma Chemical Co .Ltd, Poole.Dorset
Fluorescein (FITC) conjugated AffinitiPure Goat Anti-Mouse IgG 
DAKO
mdm2 (mouse monoclonal) Clone SMP14.
Antibody diluent solution.
Chemicon
Adenovirus anti-hexon protein (mouse monoclonal #MB805)
2.2. PRECLINICAL IN VITRO STUDIES
2.2.1. Cell cultures.
All the neoplastic kératinocytes (kindly donated by Dr K Parkinson) 
were cultured using lethally irradiated Swiss 3T3 fibroblast feeder layers 
(Rheinweld et al,1975) in DMEM (Dulbecci’s modified Eagles Medium) 
containing 10% FCS , 10% L-Glutamine and 0.4gg/ml hydrocortisone. The 
p53 sequence and protein expression of all the neoplastic cell lines have 
been previously published (Burns et al,1993). The ovarian adenocarcinoma
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cell lines A2780 and its cisplatin resistant derivative A2780Cp70 were 
grown in RPMI medium containing 10% FCS and 10% L-Glutamine. 
A2780 has wild type p53 sequence and function and A2780Cp70 has wild 
type p53 sequence which is non-functional ( Behrens et al, 1987).
2.2.2. Viruses
Onyx-015 is a chimeric human group C adenovirus (Ad2 and Ad5) 
which has a deletion between nucleotides 2496 and 3323 in the ElB region 
encoding the 55kDa protein. In addition, there is a C to T transition at 
position 2022 in E lB  which generates a stop codon at the third codon 
position of the protein. These alterations eliminate the expression of the 
55kDa protein in Onyx-015 infected cells (Barker et al, 1987).
All adenoviruses were grown on the human embryonic kidney cell 
line HEK293 which expresses the E l region of Ad2 ( Graham et al,1977) 
and band purified on a CsCl gradient. Stocks were stored at -70°C after 
addition of glycerol to a concentration of 50%vol/vol.
2.2.3. Plaque assays
Plaque assays were performed as described by Graham and 
Prevec,1991 to determine the quantity of infectious viral particles in viral 
stocks and burst assays. Briefly, plates were scraped into 0.5ml of media and 
frozen. Lysates were prepared by 3 cycles of freezing and thawing. Serial 
dilutions on the lysates were titred on HEK293 cells.
2.2.4. Replication assay
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Cell monolayers were grown to 50% confluence on 90mm plates. 
One plate was infected with Ad2 at lOpfu/cell, one plate with Onyx-015 at 
lOpfu/cell and one plate left uninfected as a control. Nonabsorbed virus was 
removed after 90 minutes and then medium with 2% FCS added. After 48 
hours incubation, the cells were harvested and collected into a cell pellet by 
centrifugation at 2,000revs/min.The cells were fixed in ice cold 70% ethanol 
for at least 1 hour, washed in PBS and then resuspended in 200 p.1 of anti- 
hexon protein antibody (Chemicon #MB805) atl/1000 dilution in PBS for 1 
hour at 37°C. The cells were washed in PBS and then resuspended in lOOpl 
of FITC labelled anti-mouse IgG (Sigma) at 1/40 dilution at room 
temperature for 30 minutes. Cells were washed in PBS and then 
resuspended in propidium iodide solution (10 ^g/ml) for 30 minutes at room 
temperature. The cells were then analysed by flow cytometry. The 
percentage of FITC staining cells was determined for Ad2 and Onyx-015 
infected cells using the control cells as a negative control for FITC. Each 
infection was determined 3 times and the mean percentage calculated.
2.2.5. Cytopathic effect(CPE) assay
Briefly, cells were grown to 70-90% confluence and then infected 
with either Onyx-015 or Ad2 for 90 minutes at MOI of 1 and lOpfu/cell. 
Plates were monitored for CPE and the assay terminated when total cytolysis 
was observed at MOI of 1 pfu/cell with wild type adenovirus.
2.2.6. Immunofluorescence for adenovirus hexon protein
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Cells were grown to 70-90% confluence and then infected with 
either Onyx-015 or Ad2 for 90 minutes at MOI of lOpfu/celL After 72 
hours, the cell sheet was scraped into the medium and pelleted by 
centrifugation at 2000revs/min for 10 minutes. The cell pellet was washed in 
PBS and then resuspended in a small volume of PBS. 25 p,l aliquots were 
pippetted onto 6mm wells on teflon coated microscope slides (DAKO. 
Product code No S6114), air dried and fixed in acetone at room temperature 
for 10 minutes. Cells were then stained with 25^1 of IMAGEN™ 
Adenovirus reagent containing an FITC labelled mouse monoclonal 
antibody to adenovirus hexon protein for 15 minutes at 37®C in a moist 
chamber, washed with PBS, air dried, then one drop of IMAGEN mounting 
fluid added and then a cover slip added. The 6mm well was then scanned 
using a confocal fluorescent microscope. Positive hexon staining was 
indicated by bright green fluorescence in the cytoplasm and/or nucleus of 
the cells.
2.3. PRECLINICAL IN VIVO STUDIES
2.3.1. Direct intratumoural injection efficacy studies.
Tumour cells (10^ cells in 200pi of PBS) were injected into the 
flanks of 6 week old female athymic nude mice and allowed to grow into 
palpable tumours (5-8mm maximal diameter). Ad2 treated tumours were 
injected with 10  ^ pfu Ad2 suspended in 100pi of PBS daily for 5 days. 
Control tumours were injected with vehicle (PBS) in an identical fashion. 
Onyx-015 treated tumours were injected with 10  ^pfu Onyx-015 in the same
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way. Tumour measurements were taken twice weekly. The animals were 
humanely killed once tumours were greater than 15mm maximal diameter.
2.3.2. Detection of virus in tumours by in-situ hybridisation.
In-situ hybridisation was performed on formalin fixed paraffin 
embedded tumours cut into 5pm sections. Slides were deparaffinised in 
xylene, hydrated through ethanols 100%, 90%, 70% and then H2O. The 
tissue was digested with proteinase K (Sigma) and post fixed in 4% 
paraformaldehyde. Hybridisation was carried out overnight at 37^C with
0.5pg/ml biotinylated adenovirus DNA probe (Enzo Diagnostics, Inc. 
Farmingdale. NY). After 3 successive washes in Ix SSC at 55^C, an alkaline 
phosphatase conjugated antibiotin antibody (Vector Laboratories) was 
applied. NBT/BCIP was used as the chromagen and slides were 
counterstained with nuclear fast red (Vector).
2.3.3. Animals and animal care.
Female athymic nu/nu mice were obtained from Harlan Orlac at 4-6 
weeks of age. Mice were housed 4 per cage in cages fitted with sterile filter 
tops and fed with sterile food and sterile water. Guidelines for animal care 
were strictly followed.
2.3.4. Analytical and statistical methods.
Mean tumour volumes in treated animals versus controls were 
compared at a given time point using the unpaired two-tailed t-test. Survival 
of animals in each group was analysed using the method of Kaplan and
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Meier, and Kaplan-Meier plots for treated and control groups were 
compared for statistical significance using the Log rank test.
2.4. PRECLINICAL p 53 STUDIES
2.4.1. Tumour collection.
Patients with recurrent squamous cell cancer of the head and neck 
gave consent for biopsies to be taken from the recurrent tumours. Core 
biopsies were taken using a 14G tru-cut needle under local anaesthetic. One 
sample was snap frozen in liquid Nitrogen for DNA extraction. One sample 
was fixed in phosphate buffered formalin , embedded in paraffin from which 
5pm sections were cut for immunohistochemical analysis.
2.4.2. Immunohistochemistry.
a) Immunohistochemistry for p53.
Immunohistochemistry was performed on formalin fixed paraffin 
embedded tumours cut into 5pm sections. Slides were deparaffinised in 
xylene, hydrated through ethanols 100%, 90%, 70% and then H2O, then 
washed in PBS (Phosphate buffered saline). Antigen retrieval was carried 
out by microwaving in citrate buffer pH6.0 at 500W for 25 minutes and then 
allowed to cool over 20 minutes. The slides were washed in PBS for 5 
minutes and then endogenous peroxide activity blocked with 3% v/v 
hydrogen peroxide in methanol for 10 minutes. After washing in PBS for 5 
minutes, the slides were blocked with Universal blocking solution
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(Biogenex) for 10 minutes, and then primary antibody ( DO-1 Oncogene 
Science ) at a dilution of 1/1000 in DAKO antibody diluent solution, added 
for 1 hour at room temperature. Antigen detection was done using a 
biotinylated secondary antibody followed by streptavidin. The chromogen 
used for detection was diaminobenzidine (Vector) for 3-10 minutes. The 
sections were counterstained with haematoxylin , dehydrated in graded 
alcohols followed by xylene, and then mounted in DPX mounting medium 
(BDH Chemicals). The immunohistochemistry pattern was scored using a 
histoscore based on intensity of staining and percentage of positive cells 
staining and given a score out of a maximum of 6.
Intensity o f staining Score %cells staining positive Score 
None 0 0 0
Mild 1 5-20% 1
Moderate 2 20-80% 2
Severe 3 >80% 3
b) Immunohistochemistry for mdm2
The protocol used was as described for p53 immunohistochemistry. 
The primary antibody used was a mouse monoclonal antibody clone SMP14 
(DAKO) at a dilution of 1/50 in DAKO antibody diluent solution for 1 hour 
at room temperature. Mdm2 staining was then scored by the percentage of 
cells staining positive and by the intensity of staining.
2.4.3. DNA extraction.
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Genomic DNA was isolated directly from frozen tumours by lysis 
buffer containing lOmM Tris-HCl, lOmM EDTA, lOmM NaCl, 4% N-lauryl 
sarcosine and 2.75mg/ml proteinase K, followed by overnight digestion at 
55^C and EtOH precipitation. The resulting pellet was washed with 70% 
EtOH , dried, and resuspended in lOOpl TE and stored at 4°C.
2.4.4. p53 sequencing.
Exons 4 to 9 were sequenced using DNA extracted from tumour 
biopsies. This was done by Oncormed Corporation,Gaithersburg,Maryland.
2.4.5. HPV analysis.
The presence of HPV in tumour DNA was assessed by PCR. The 
primers for the amplification of HPV-16 and HPV-18 have been described 
previously (Yeudall et al,1991) and amplify fragments of the E6/E7 (HPV- 
16) or E6 regions (HPV-18) which are 165 and 99bp respectively. HPV 33 
primers were those as described by Haraf et al,1996.
The HPVI6 primers were
5’ TTAATTAGGTGTATTAACTG3’
5' TGCATGATTACAGCRGGGTT3’
The HPVI8 primers were
5 ATCTGTGTGCACGGAACTAAC3 ’
5 ’ AATGCAAATTCAAATACCTC3 ’
The HPV33 primers were
5’GTGCCAAGCATTGGAGACAA3’
5’GATAAGAACCGCAAACACAG3’
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SiHa DNA (single copy HPV 16) and HeLa (HPVI8) were used as 
positive controls. HPV amplification was carried out at 95*^ C for 3 minutes, 
then 30 cycles of 95°C for 30s, 55^C for 30s, 72^C for 30s, followed by a 
final extension time of 10 minutes at 72^C. An aliquot was run on a 1% 
agarose gel (Nu-Sieve) containing 0.5p,g/ml ethidium bromide in TBE 
buffer and then photographed under UV light to check for correct 
amplification.
2.5. PHASE I CLINICAL TRIAL - Single injection protocol.
2.5.1. Enrollment criteria.
A total of 22 patients with recurrent head and neck cancer were 
entered into the trial from 2 centres -  11 from Glasgow, Scotland and 11 
from San Antonio, USA. Eligibility requirements included histologically 
confirmed squamous cell carcinoma of the head and neck which was 
recurrent and refractory to radiotherapy and/or chemotherapy. The tumour 
had to be amenable to direct injection and measurement either clinically or 
radiographically. The tumours had abnormal p53 by immunohistochemistry. 
All patients had a Karnofsky Performance Status of greater than or equal to 
60%, life expectancy of greater than 3 months and were over 18 years of 
age. All patients had adequate haematological, renal and hepatic function. 
The maximum allowed creatinine was 1.5mg/dl, maximum allowed 
Aspartate transaminase (AST) and Alanine transaminase (ALT) was 2.5 fold 
the upper limit of normal, minimum allowed haemoglobin 9gm/dl,
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minimum allowed white cell count of 3,000/pl (neutrophils 1,500/pi) and 
minimum platelet count of 100,000/pl. Patients had not received any 
chemotherapy or radiotherapy within 4 weeks of study entry. All patients 
gave written informed consent. The protocol was approved by the US Food 
and Drug Administration (FDA), the UK Gene Therapy Advisory 
Committee (GTAC), and the local institutional review board ethics 
committees.
2.5.2. Onyx-015.
Onyx-015 is a chimeric human group C adenovirus (Ad2 and Ad5) 
which has a deletion between nucleotides 2496 and 3323 in the E lB  region 
encoding the 55kDa protein. In addition, there is a C to T transition at 
position 2022 in E lB  which generates a stop codon at the third codon 
position of the protein. These alterations eliminate the expression of the 
55kDa protein in Onyx-015 infected cells (16). Sterile purified lots of virus 
were produced for human clinical use by MAGENTA Corporation 
(Rockville,MD) and tested for titre, sterility and general safety by 
Microbiological Associates using FDA approved test methods.
2.5.3. Treatment Protocol.
Pre-treatment evaluation included complete blood cell count with 
differential, coagulation screen, routine biochemistry profile, urinalysis, 
CXR and ECG. All patients had a core biopsy of the recurrent tumour for 
p53 evaluation by immunohistochemistry and gene sequencing. CD4 
lymphocyte counts were carried out to determine the immune status of the
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patients. The size of the recurrent tumours was measured clinically and also 
by ultrasound, CT scan or MRI scan.
The volume of the injected tumour was determined either by clinical 
measurement or radiological measurement, depending on the site of the 
tumour. Vials of Onyx-015 were then thawed and diluted with diluent 
(electrolyte 48 solution) to a volume equivalent to 30% of this estimated 
tumour volume.The tumour to be injected was mapped into Icm^ areas and 
then equal volumes of solution were injected into each area. Subcutaneous 
injection of local anaesthetic was used in some patients to prevent pain on 
injection. Patients then had vital signs recorded every 20 minutes for 2 
hours, 2 hourly for the next 22 hours , then 6 hourly for the next 24 hours. 
Patients were then discharged home if vital signs were normal.
Follow up was twice weekly. Blood counts and biochemistry were 
carried out weekly. Blood samples were taken weekly for PCR for 
adenoviral DNA and to determine neutralising antibody titers to adenovirus. 
Swabs of the injection site and oropharynx taken pre-treatment and 8 days 
post-treatment were assessed for adenovirus by a direct immunofluorescent 
assay against adenoviral hexon protein. Tumour core biopsies were taken at 
days 8 and 22 and examined for adenoviral replication by in-situ 
hybridisation and for evidence of necrosis. Tumour measurement was 
carried out clinically and radiographically at 4 weeks. Patients were eligible 
for re-treatment with virus injections at 4 weeks (up to a maximum of 5 
cycles) if measurements indicated response or stable disease in the injected 
tumour (see below), there was no dose-limiting toxicity (see below) and 
there was no evidence of disease progression at other sites. Ethical approval
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was given for an additional injection of diluent alone into separate lesions 
using the same injection technique as for Onyx-015. The aim was to assess 
the volume effect of control intratumoural injection and this was carried out 
in 3 patients.
2.5.4. Evaluation of toxicity and response.
Toxicity was assessed using NCIC Toxicity Criteria. The Maximum 
Tolerated Dose (MTD) was defined as the dose at which 2 patients 
experienced a Dose Limiting Toxicity (DLT) after the first treatment with 
Onyx-015. The Dose Limiting Toxicity was defined as either a Grade 4 
toxicity for flu-like symptoms due to Onyx-015, a Grade 4 toxicity for local 
reaction at the Onyx-015 injection site or any other toxicity of grade 3 
severity due to Onyx-015. A minimum of 3 patients were treated at each 
dose level. If one of the 3 patients had a DLT, a total of 6 patients would be 
treated at that cohort. An escalation scheme was devised to permit rapid but 
safe increase in dose with a maximum of 10^  ^ pfu set. The 10^  ^ pfu limit 
was based on manufacturing limits. No intra-patient dose escalation was 
permitted.
Response to therapy was assessed after each cycle by clinical and 
radiological tumour measurement. All radiological measurements were 
made by the same radiologist. Since Onyx-015 caused substantial tumour 
necrosis centrally rather than uniform tumour shrinkage peripherally, the 
non-necrotic tumour area was determined and used to assess injected tumour 
response. These injected tumour responses were then classified as partial 
response (PR) if there was a greater than 50% reduction in the treated
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tumour, minor response (MR) if there was a greater than 25% but less than 
50% reduction in the treated tumour, stable disease (SD) if there was less 
than a 25% increase or decrease in the treated tumour and progressive 
disease if there was a greater than 25% increase in the injected tumour or the 
appearance of new lesions. Detailed responses are reported on a case-by- 
case basis because of the use of this non-conventional measurement 
methodology. To control for the effect of diluent, 3 patients who had more 
than 1 tumour had 1 tumour injected with Onyx-015 and another injected 
with diluent only.
2.5.5. Evaluation of p53 status.
1. Immunohistochemistry.
As described previously.
2.Gene sequencing.
Exons 4 to 9 were sequenced on pre-treatment tumour biopsies by 
Oncormed Corporation, Gaithersburg, Maryland.
2.5.6. In-situ hybridisation.
In-situ hybridisation was performed on formalin-fixed paraffin 
embedded tumours cut into 5[xm sections. Slides were deparaffinised in 
xylene, hydrated through ethanols 100%, 90%, 70% and then H2O. The 
tissue was digested with proteinase K and post-fixed in 4% 
paraformaldehyde. Hybridisation was carried out overnight at 37^C with 
0.5p.g/ml biotinylated adenovirus DNA probe (Enzo Diagnostics, Inc. 
Farmingdale, NY). After 3 successive washes in Ix SSC at 55°C, an alkaline
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phosphatase conjugated antibiotin antibody (Vector Laboratories) was 
applied. NBT/BCIP was used as the chromagen and slides were 
counterstained with nuclear fast red (Vector).
2.5.7. Adenoviral PCR.
The presence of adenovirus in plasma samples from patients was 
determined by PCR using primers to the E l A region of the adenoviral 
genome. This was carried out by Onyx pharmaceuticals.
2.5.8. Direct immunofluorescent assay for hexon protein.
Swabs from the injection site and oropharynx were placed in viral 
culture medium. Human embryonic kidney cells (HEK293) were grown to 
70-90% confluence and then inoculated with this medium. After 72 hours, 
the cell sheet was scraped into the medium and pelleted by centrifugation at 
2000revs/min for 10 minutes. The cell pellet was washed in PBS and then 
resuspended in a small volume of PBS. 25 pi aliquots were pippeted onto 
6mm wells on teflon coated microscope slides (DAKO. Product code No 
S6114), air dried and fixed in acetone at room temperature for 10 minutes. 
Cells were then stained with 25 pi of IMAGEN™ Adenovirus reagent 
containing an FITC labelled mouse monoclonal antibody to adenovirus 
hexon protein for 15 minutes at 37°C in a moist chamber, washed with PBS, 
air dried, then one drop of IMAGEN mounting fluid added and then a cover 
slip added. The 6mm well was then scanned using a fluorescent microscope. 
Positive hexon staining was indicated by bright green fluorescence in the 
cytoplasm and/or nucleus of the cells.
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2.5.9. Determination of neutralising antibody titres
Patient and control samples were incubated at 55°C for 30 minutes to 
inactivate complement. Clinical plasma samples previously determined to 
produce high, midrange and negative titres were designated as plasma 
controls. Each dilution was mixed with adenovirus stock at a titre pre­
qualified to produce 15-20 plaques per well of a 12 well dish in DMEM 
growth medium. The patient’s samples and controls were inoculated for 1 
hour at room temperature, and applied to 70-80% confluent JH393 cells in 
12 well dishes. After 2 hours of incubation at 37°C, 5% CO2 plasma-virus 
mix was removed and 2ml of 1.5% Agarose in DMEM was added to each 
well. Plates were read on day7 post-inoculation by counting the number of 
plaque forming units (pfu) per well. The titre of neutralising antibody for 
each sample was reported as the dilution of plasma that reduced the number 
of plaques to 60% of the number of plaques in the virus control without 
antibody.
2.6. PHASE I TRIAL - multiple injection protocol.
A total of 10 patients with recurrent head and neck cancer were 
recruited. Eligibility criteria were identical to the single injection protocol. 
The injection procedure was identical except that patients received 5 daily 
injections at the same viral dose per injection. 4 patients were treated at 5 x 
10  ^pfu and 6 patients at 5 x 10^° pfu. The total dose of virus administered in 
each of these cohorts was less than the maximum dose given in the single 
injection protocol (lO^^pfu) and therefore we did not expect to see any
73
increase in toxicity. Evaluation of toxicity, tumour response, p53 status and 
viral replication assays were as described for the single injection protocol.
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Chapter 3
Results
3.1. PRECLINICAL IN VITRO STUDIES.
3.1.1. Onyx-015 causes lysis of p53 deficient head and neck squamous 
cell cancer cell lines.
A panel of head and neck squamous cell cancer cell lines were tested 
for sensitivity to cytopathic effects induced by Onyx-015 and wild type 
adenovirus. The p53 sequences and protein expression for all cell lines has 
previously been carried out and are shown in Table 1 (Burns et al,1993). All 
HNSCC cell lines tested have mutant p53 except cell line BICR19 which 
has a wild type p53 allele and a mutant p53 allele. The ovarian 
adenocarcinoma cell line A2780, which has wild type p53 sequence and 
function as determined by radiation induced G1 arrest, was used as a 
negative control for CPE. The isogenic cisplatin resistant ovarian 
adenocarcinoma cell line A2780Cp70, which has wild type p53 sequence 
but is non-functional, was used as a positive control for CPE. We have 
previously shown that both cytolysis and viral replication is x 5-10 greater in 
A2780Cp70 compared to A2780 (Kim Tae Young,unpublished results). 
Table 2 shows the cell lines tested and results of CPE assays. Figure 8 
shows examples of CPE in different cell lines tested 5 days following virus 
infection. From Table 2, all HNSCC cell lines with mutant p53 showed 
cytolysis with Onyx-015. The cell line A2780 showed no CPE with Onyx- 
015 but was positive with wild type virus. Interestingly, the cell line 
BICR19 , which has 1 allele with wild type p53 showed no cytolysis with 
Onyx-015 suggesting that the wild type allele is still functional and is able to 
prevent Onyx-015 replication and cytolysis.
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Cell line p53 CPE CPE
Onyx-015 Ad2
A2780 wt - +
A2780Cp70 wt + +
SCC4 mut + +
SCC9 mut +
s e e  15 mut + +
BICR16 mut +
BICR19 wt/mut - -t-
BICR78 mut +
Table 2
Cytopathic effect (CPE) of wild type adenovirus (Ad2) and Onyx-015 infection on 
HNSCC cell lines. The CPE studies were carried out using multiplicities of infection 
(MOI) of I and 10 pfu/cell to infect cell monolayers. Infections with Onyx-015 were 
scored for CPE on the day in which wild type adenovirus had induced CPE in all cells at 
an MOI of 1 pfu/cell. The “H-” and refer to the presence or absence of CPE.
Control
(dayS)
Ad2
(dayS)
Onyx-015
(dayS)
S ' - V A 2 7 8 0
s e e  15
; - v * >  ? :
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Figure S. Cylcpalhic etïecl(CPE) ol wild type adencvirus (Ad2) and Onyx-015 Inlcclicn 
on HNSCC cell lines al day 5 post virus inleedcn. Pcsiiive CPE is indicated by the typical 
“bunches of grapes" appearance of adenovirus infected cells. Cell line A2780 showed 
cytolysis with Ad2 hut not Onyx-015. The cell lines SCC9. SCC15 and BlCRIb show 
cytolysis with both Ad2 and Onyx-015.
3.1.2. Mutant p53 HNSCC cell lines infected with Onyx-015 allow viral 
replication.
To determine if cytolysis induced by Onyx-015 was due to 
replication of virus, cells were harvested 48 hours post infection and stained 
with an anti-hexon protein antibody. Hexon protein is a capsid protein 
which is synthesised in the late phase of viral DNA replication and is 
therefore a marker for viral replication. Table 3 shows the results of hexon 
protein staining assays. Figure 9 shows confocal microscopy pictures of 
hexon staining in the cell lines tested. All cell lines which were positive for 
CPE were also positive for hexon protein indicating that cytolysis and viral 
replication selectively occurred in the cell lines with mutant p53.
3.1.3. Quantification of viral replication of Onyx-015 in HNSCC cell 
lines by FACS analysis.
To quantify the amount of viral replication occurring in the cell lines, 
a FACS analysis assay was developed by measuring the number of hexon 
protein positive cells using an FITC labelled anti-hexon protein mouse 
monoclonal antibody. The percentage of positive cells with Onyx-015 was 
determined and expressed as a ratio in relation to the percentage positivity 
with wild type adenovirus. Each infection was carried out 3 times for each 
cell line and the mean percentage hexon positivity determined. Table 4 
shows the results of the cell lines tested and Figure 10 shows typical FACS 
analysis plots for cell lines A2780 and A2780cp70. From Table 4, we can 
conclude that all mutant p53 cell lines show a x2-6 fold increased 
replication relative to the control cell line A2780. The cell line BICR19,
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Cell line p53 Hexon staining
Onyx-015 Ad2
A2780 wt - +
A2780Cp70 wt + +
SCC4 mut +
SCC9 mut + +
s e e  15 mut + +
BICR16 mut + +
BICR19 wt/mut -
BICR78 mut + +
Table 3
Hexon protein staining of wild type adenovirus (Ad2) and Onyx-015 infected 
HNSCC cell lines. Cell monolayers were infected at a MOI of 10 pfu/cell and cells 
har vested 48 hours postinfection. Cells were stained for hexon protein expression using an 
FITC labelled anti-hexon protein mouse monoclonal antibody and then visualised using a 
fluorescent confocal microscope. Cells positive for hexon protein stained green and 
negative cells stained red with Evans blue counterstain.
Ad2 Onyx-015
A2780
•  *
*  M
SCC9
Figure 9.
Hexon protein suuning of wiki tyi^ e Atl2 and Onyx-015 infected cells. Cells are 
stained with an FITC labelled anti-hexon protein tnon.se tnonoclonal antihrxly Green 
staining cells represent hexon jiosiiive cells. Nonintected cells ;ue stained red with the 
coiiniersiain Evans blue.
Cell line p53 Ad2 s.e. Onyx-015 S.e. Ratio Onyx/Ad2
%
A2780 wt-funct' 65.7 15 8.7 4.7 13.2
A2780Cp70 wt-nonfunct' 84 5.1 54 2.7 64.3
SCC4 mutant 56 12.8 15.3 1.9 27.3
SCC9 mutant 78.2 8.2 30.8 7.6 39.4
SCC15 mutant 81.1 8.8 33.1 2.8 40.8
BICR16 mutant 52.1 3,9 25.1 4.3 48.2
BICR19 mutant 94.1 0.9 2.3 0.01 2.4
BICR78 mutant 48.8 15.4 40.3 21.8 82.6
T able 4
Percentage hexon positive cells quantified by FACS at a MOI of lOpfu/cell for 48 
hours. Cell monolayers were infected at MOI of 10 pfu/cell and the cells then harvested at 
48 hours post infection. Cells were stained with anti-hexon protein antibody linked to FITC . 
Cells were counterstained with propidium iodide. Mock infected cells were used for each 
cell line to determine the baseline FITC signal. The percentage of cells staining positive in 
infeeted cells was determined relative to the mock infected FITC signal. Each infection was 
carried out 3 times per cell line and the mean percentage hexon positivity determined.
Control
48hrs
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Figure 10. FACS analysis of viral replication of Onyx-015 in A2780 and Cp70 
by FITC labelled hexon protein quantification.
Cell monolayers were infected with Onyx-015 at a MOl of lOpfii/cell for 48hours 
and then cells were harvested and stained with an anti-hexon protein antibody linked 
to FITC. The cells were then counterstained with propidium iodide and then 
analysed by tlow cytometry. The percentage of cells positive for hexon protein is 
indicated by the right upper and right lower quadrants. Nonspecific staining is 
indicated by cells to the left of the vertical line- the left upper and left lower 
quadrants. For A2780( functional p53). the hexon positivity is 13% and for Cp7() 
(nonfunctional p53) the hexon positivity is 82%. 1 his indicates the selective 
replication for Onyx-015 for cells with nonfunctional p53.
which has a functional p53 allele, showed very high replication with Ad2 
infection but very low replication with Onyx-015. The replication ratio was 
much lower than the control cell line A2780. This again indicated that only 
one functional p53 allele is necessary to prevent Onyx-015 replication.
In conclusion, these in-vitro studies showed that the E lB  attenuated 
adenovirus, Onyx-015, replicated more efficiently in head and neck tumour 
cell lines with non-functional p53. This supported the previous published 
work in other tumour types (Bischoff et al,1996).
3.2. PRECLINICAL IN VIVO STUDIES.
3.2.1. Anti-tumour activity of Onyx-015 in BICR16 subcutaneous 
xenografts.
The mutant p53 HNSCC cell line BICR16 was selected for in-vivo 
testing. This is a cell line derived from a patient with recurrent head and 
neck cancer and was therefore representative of tumours in the phase I trial. 
Subcutaneous xenografts were formed in nude mice and once tumours were 
5-lOmm in maximum diameter, the tumours were injected at lO^pfu with 
either wild type adenovirus or Onyx-015 daily for 5 days. Control tumours 
were injected with diluent of PBS. Tumour diameters were then measured 
twice weekly and growth curves plotted. Figure 11a shows the growth 
curve for Ad2 and Figure 11b shows the growth curve for Onyx-015 (also 
called dll520). Control tumours continued to grow exponentially whereas 
Ad2 and Onyx-015 injected tumours underwent tumour regression. Both 
curves were statistically analysed using unpaired two-tailed t-test and found 
to be statistically significant. The p-value for Ad2 versus Control was 0.002
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a p=0.002(very significant)
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Figure 11.
Direct intratumoural clllcacy studies in 1Î1CRI6 nude mouse xenografts. Suhcutaneous 
xenogralts were formed in the Hanks of 6 week old female nude mice. Once tumours were 5- 
lOmm max. diameter, they were injected with either wild type adenovims (Fig 1 la) or Onyx-Ol.S 
(Fig 1 in) daily for 5 days. Control tumours were injected with FliS. Tumour si/e was measured 
twice weekly . p-values were calculated using unpaired two-tailed t-test.
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(very significant) and the p-value for Onyx-015 versus Control was <0.001 
(highly significant). Figure 12a shows control and virus injected mice. 
Control mice showed evidence of weight loss as tumours continued to grow 
exponentially. In contrast, the virus injected tumours underwent necrosis 
often with some ulceration of the overlying skin. In addition, there was no 
evidence of cachexia in the virus injected mice.
3,2.2. Anti-tumour activity of Onyx-015 is due to viral replication.
To determine whether or not tumour regression was due to viral 
replication, it was necessary to show the presence of viral replication in the 
injected tumours. Tumours were stained by in-situ hybridisation using a 
probe against adenoviral DNA. Figures 12b and 12c show examples of 
typical staining seen. The cells staining positive were always located at the 
border between necrosis and viable tumour. All viral injected tumours 
stained positive by in-situ hybridisation. These results suggested that the 
tumour regression observed in the mouse model was due to viral replication.
3.3. PRECLINICAL u53 STUDIES
Currently available therapies for recurrent head and neck cancer 
including reirradiation (Nickers,1997) and chemotherapy (Clavel,1994) all 
have poor response rates which are short lasting (Forestiere,1994). The 
reason for this is unclear but is likely to be multifactorial in nature. One 
factor which may be important in resistance to therapy is loss of function of 
the tumour suppressor gene p53. It has been shown that inactivation of the 
p53 tumour suppressor gene is one of the major predictors of failure to
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respond to radiotherapy and chemotherapy in many tumour types 
(Mcllwrath et al,1994; Buttitta et al, 1997; Cutilli et al, 1998). This is 
because p53 plays a major role in the induction of apoptosis in response to 
genotoxic agents such as radiotherapy and chemotherapy (Huang et al,1996; 
Lowe et al,1993). Therefore one possible explanation for the poor response 
rates in recurrent HNSCC to radiotherapy and chemotherapy could be due to 
a high incidence of p53 inactivation in this disease. No previous studies 
have been reported on the incidence or mechanism of p53 inactivation in 
recurrent head and neck cancer. We therefore wanted to determine the 
incidence of p53 mutations in this disease and also gain insight into other 
mechanisms of p53 inactivation such as binding by the cellular protein 
mdm2 (Haupt et al,1997; Oliner et al,1992) and viral protein HPV E6 
(Lechner et al, 1992; Scheffner et al, 1990). To determine the incidence of 
p53 inactivation in recurrent HNSCC, 22 recurrent tumours from patients 
previously treated with radiotherapy +/- surgery were analysed. The p53 
status of each tumour was analysed by sequencing and by 
immunohistochemistry. Tumours were further analysed for mdm2 
overexpression by immunohistochemistry and for HPV infection by PCR of 
tumour DNA.
3.3.1. Primary tumour, site of recurrence and previous treatment.
The primary tumour, site of recurrence and previous therapy for each patient 
studied are shown in Table 5. The mean age was 64 and the male to female 
ratio was 14:8. All patients had received radiotherapy. In addition, 4 patients 
had received chemotherapy and 14 patients had had surgery. The site of
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tumour recurrence was most commonly regional in the site of draining 
lymph nodes.
3.3.2. Incidence of p53 mutation in recurrent HNSCC is high and type 
of mutation correlates with immunohistochemistry.
The p53 sequence and immunohistochemistry for each tumour is 
shown in Tables 6 and 7. Of the 22 tumours studied, 15 had mutations in 
the p53 gene of which 6 were missense mutations and 9 were nonsense 
mutations. Generally, the immunohistochemistry pattern correlated directly 
with the type of p53 mutation i.e. missense mutations gave high scores and 
nonsense mutations gave low scores. One patient (patient 6) had a nonsense 
mutation yet stained positively by immunohistochemistry. The site of the 
mutation in this patient’s p53 gene was in codon 9 and this would account 
for its detection by immunohistochemistry using the DO-1 antibody. Of the 
7 patients with wild type p53 sequence, 5 were negative on 
immunohistochemistry (tumours 10, 11, 14, 17, 19) and 2 were positive 
indicating overexpression of wild type p53 (tumours 9, 21). Examples of 
p53 immunohistochemistry with the relevant histoscores are shown in 
Figure 13.
3.3.3. Incidence of HPV infection and mdm2 overexpression.
These results are shown in Table 7. 8 tumours were positive for 
HPV DNA, all of which were serotype HPV 16. Of these, 5 were in tumours 
with mutant p53 and 3 were in tumours with wild type p53. A typical 
positive PCR reaction for HPVI6 is shown in Figure 14.
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Figure 14. HPV 16 E6/7 analysis o f  tumour DNA by PCR.
D N A  f r o m  S i H a  cel l  line w a s  used  as a pos i t i ve  c o n t r o l  for  
H P V  16 E6/7 .  T u m o u r  17 is pos i t ive  for  H P V  16 with the co r r ec t  
P C R  p r o d u c t  at 165 base  pairs.
Mdm2 expression was detected in 11 of the 22 tumours (50%). Of 
these, 5 were weakly positive (histoscore=2, 3) and 6 were strongly positive 
(histoscore=4, 5, 6). Mdm2 expression was present in 7 tumours with 
mutant p53 and in 4 tumours with wild type p53.
Of the 5 tumours with wild type p53 sequence and negative or 
wealdy positive p53 immunohistochemistry, 2 had HPV 16 expression 
(tumours 10,19), 1 had high expression of mdm2 (tumour 11), 1 tumour had 
both (tumour 17), and 1 had neither. Of the 2 tumours with wild type p53 
and strongly positive p53 immunohistochemistry (tumours 9, 21), both had 
high expression of mdm2 indicating inactivation by mdm2. Thus, 6 of the 7 
tumours with wild type p53 had inactivation of p53 either by HPV 16 
infection or by overexpression of mdm2. Examples of mdm2 
immunohistochemistry in tumours 17 and 21 are shown in Figure 15.
Thus, overall we have shown that in recurrent HNSCC the incidence 
of p53 alterations is very high at 95%. We therefore considered recurrent 
head and neck cancer to be a suitable tumour type in which to carry out a 
phase I study using Onyx-015. Two phase I trials were carried out- a single 
injection protocol involving 22 patients and a multiple injection protocol 
involving 10 patients.
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3.4. CLINICAL PHASE I STUDY - single iniection protocol.
3.4.1. Patient characteristics
The characteristics of the patients treated are shown in Table 8. All 
22 patients treated were evaluable for toxicity and efficacy. 17 patients were 
male and 5 were female. The mean age was 63 and all patients had a 
performance score equal to or above 60% with a median of 80%. 21 
patients had had prior therapy. 20 patients had received radiotherapy either 
alone or in combination with surgery and/or chemotherapy. 8 patients had 
received chemotherapy in combination with either radiotherapy or 
radiotherapy and surgery.
The most common site of recurrence was in the neck (regional 
recurrence) in the cervical area. Other sites included intraoral, preauricular, 
clavicular, facial and lip recurrences. The size of the recurrent tumours 
varied over a range from 2.2cm^ to 20 cm^ with the median being 11.8 cm^. 
Examples of patients treated are shown in Figure 16.
A total of 22 tumours were positive for p53 by 
immunohistochemistry. Not all tumours had mutant p53 on gene sequencing 
however. 16 tumours had mutant p53 sequence, 5 had wild-type p53 
sequence and 1 was non-interpretable. An example of typical positive p53 
staining is shown in Figure 17. The pre-treatment immune status of each 
patient, as assessed by CD4 lymphocyte count, showed that most patients 
were immunosuppressed with 19 of the 22 patients having a CD4 count less 
than 500 and only 3 having a count greater than 500. 13 of the 22 patients 
had pre-existing neutralising antibodies to adenovirus.
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A ge(years) M edian 63
Range 32-81
Sex Male 17
Female 5
Performance status 90% 3
80% 11
70% 5
60% 3
Prior therapy Surgeiy+X RT 10
C hcino+X R T 4
S urgcry+ XRT+C he mo 4
Radiotherapy alone 2
Surgery alone 1
None 1
Location of recurrence Cervical 10
Supraclavicular 2
Facial 2
Tongue 2
O ral 2
O ther 4
Tumour size-cm" M edian 11.8
Range 2.2-20
p53 gene sequence M utant 16
(exons 4-9) Wild type 5
N oninterpre table I
Baseline neutralising antibody Positive 13
levels Negative 9
CD4 counts <500 19
(range 152-1050) >500 3
Table 8. Baseline patient characteristics.
Figure 16.
E xam ples  o f  le c u n e n l  head and neek cancers . Fig 16a shows a palient with a regional K innh node 
recurrence in the right neck i io in  a Ihxn ol motilh primary Itimotir Fig I6h show s a patient with 
local rec t inen ce  in the le It neck Irom a tell tonsillar primary Itimotir. Fig 16c shows a patient with a 
lell s tihmandibtilar rec t inen ce  Irom an anter ior Ihxir ol mouth primary  Itimotir Fig 16d shows a 
palient with a left c lav icu lar subcu taneous  recurrence  Irom a laryngeal p rim ary  tum our
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3.4.2. Toxicity and safety
Table 9 summarises the treatments given. Of the 22 patients, 14 
received 1 cycle, 6 received 2 cycles, 1 received 3 cycles and 1 received 4 
cycles. Therefore a total of 33 cycles were given. Intratumoural injection of 
Onyx-015 was well-tolerated with no dose-limiting toxicity being obseived. 
Toxicities probably or possibly related to Onyx-015 are shown in Table 10 
and are all of grades I/II. The most frequent symptom was fever of Grade 
I/II. Two patients experienced discomfort during the injection which 
subsided within 1 hour in both patients. One patient had Grade II symptoms 
of tracheal obstruction which may have been related to Onyx-015. Serial 
blood counts showed no evidence of myelosuppression. Lymphocytopenia 
(Grade II - Grade IV) was seen in 5 patients, but this antedated virus 
injection and presumably related to pre-existing immunosuppression. There 
was no evidence of any other haematological or biochemical abnormality 
attributable to therapy. Patients who were retreated did not experience any 
further toxicity suggesting that neutralising antibody levels did not sensitise 
the patients to added toxicity.
All patients had blood plasma samples collected before and after 
virus injection (days 0, 3, 8, 15, 22 and 29). DNA was isolated from these 
plasma samples and PCR analysis was carried out using primers specific for 
adenovirus. All of these samples were negative suggesting Onyx-015 was 
not shed or did not persist in the circulation. All patients had swabs taken 
from the oropharynx and the injection site to detect virus shedding on days 
0, 8,15, 22 and 29. These swabs were analysed by a direct fluorescent hexon
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Cohort No.patients No.cycles Targei tumour response
1 2 3 4 PR MR SD Prog
lO^pfu 5 2 1 1 1 1 0 1 3
lO^pfii 4 4 0 0 0 0 0 2 2
lO^pfu 4 2 2 0 0 2 0 1 1
BxiO^pfu 3 2 1 0 0 0 1 1 1
3 2 1 0 0 0 0 2 1
io“ pfti 3 2 I 0 0 0 1 1 1
Total 22 14 6 1 1 3 2 8 9
Table 9. Patients treated per cohort and target tumour response at >4 weeks 
using non-conventional measurements.
Toxicity profile - ail Grade I/II
Toxicity Cycle 1 All cycles, n=33
Fever 7(32%) 7(21%)
Nausea 3(14%) 3(9%)
Chills 2(9%) 2(6%)
Flu syndrome 2(9%) 2(6%)
DiaiThoea 2(9%) 2(6%)
Pain(tumoui’) 2(9%) 2(6%)
Vomiting 1(4%) 1(3%)
Tracheal obsü'uction 1(4%) 1(3%)
Table 10. Toxicity profile for first cycle and all cycles.
protein assay and all were negative suggesting Onyx-015 was not readily 
shed from treated tumours even when the tumour was ulcerated.
3.4.3. Tumour response and correlation to p53 status.
All patients were evaluable for response and the data are summarised 
in Table 9. Ultimately, all patients in the study progressed due to the 
development of other neck lesions or due to distant métastasés in the lung, 
liver or bone. However, if we consider only the tumours which were 
injected, then there was evidence of antitumour activity. A common finding 
following injection was that the injected tumour became soft and fluctuant, 
usually within 8 days following injection. Often the overlying skin became 
erythematous. MRI scans of injected tumours often showed a change in the 
signal from the tumour centre, in keeping with liquefaction of solid tumour, 
i.e. necrosis. Using non-conventional criteria for measuring the degree of 
tumour shrinkage (i.e. subtracting out central necrosis), 3 patients showed a 
partial response in the treated lesion and 2 showed a minor response. A 
further 8 patients had stable disease. There was no correlation between viral 
dose injected and tumour response.
Details of the 3 cases showing a substantial tumour shrinkage in the 
treated lesion are as follows:
1. Patient 1003: had a primary tongue tumour treated with surgery, 
radiotherapy and chemotherapy. He developed a recurrence in the right 
submandibular area with severe trismus and pain. This area was injected 
with lO^pfu of virus. A 50% reduction in the size of the tumour occurred 
with 3 cycles of treatment given over 12 weeks. The MRI scans pre and
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post-treatment showing changes suggestive of necrosis are illustrated in 
Figure 18. Symptomatically he improved with increased jaw mobility and 
reduced pain. This response was of 12 weeks duration before the patient was 
removed from study due to the development of lung métastasés.
2. Patient 1007: had a left temple tumour treated initially with surgery and 
radiotherapy. He developed a recurrence in the left preauricular area 
extending deep into the pterygoid fossa. This was injected at lO^pfu and a 
75% reduction in size of the tumour, with radiological changes in keeping 
with necrosis, occurred after 2 cycles of treatment. This response was of 8 
weeks duration before the patient was removed from study due to the 
development of orbital disease requiring radiotherapy.
3. Patient 2006: had a primary tongue tumour treated with radiotherapy. He 
developed a tongue recurrence and the right third of the tongue was injected 
at lO^pfu. A large portion of tumour, measured as 80% of the original 
injected tumour, sloughed off on day 8. This response was of 4 weeks 
duration before the patient died from bacterial pneumonia ( believed to be 
unrelated to virus injections).
Of the 2 patients with a minor response to treatment, 1 patient was 
removed from study at 4 weeks due to the development of a second 
locoregional recurrence and 1 patient was removed at 4 weeks for 
radiotherapy to the target treated tumour (This patient had not received prior 
radiotherapy and this had been planned prior to virus injection). Of the 8 
patients with stable disease, 3 were removed from study due to the 
development of a second locoregional recurrence - 1 patient at 8 weeks and 
2 patients at 4 weeks. The other 5 patients were removed from study due to
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progression at the injected tumour at 4-6 weeks post virus injection. All 
other patients showed evidence of tumour progression locally and at other 
sites.
To control for the effect of diluent, 3 patients had satellite lesions 
injected with diluent alone. All of these tumours progressed with no clinical 
or radiological signs suggestive of necrosis.
The p53 status of tumours versus the tumour response is shown in 
Table 11. Of the 5 tumours which showed evidence of response, 4 had 
mutant p53 and 1 had wild type p53 suggesting that Onyx-015 may 
selectively replicate in mutant p53 tumours. However, if we compare the 
p53 status of tumours showing evidence of response (MR,PR) to those 
which did not (SD,Prog), statistical analysis using Fisher’s exact test showed 
no significant correlation (p= 0.53).
3.4.4. Detection of Onyx-015 in tumour and correlation to p53 status.
Adenoviral DNA was detected in tumour biopsies by in-situ 
hybridisation. A typical example of staining is shown in Figure 19. 4 of the 
22 patients showed positive evidence of viral replication on the biopsies 
obtained. All 4 of these patients had mutant p53 on gene sequencing. No 
patients with wild type p53 gene sequence showed virus replication. In 
addition, adenoviral DNA was only detected in tumour cells and normal skin 
and mesenchymal tissue within the biopsies were negative. This suggested 
that viral replication was selective for tumours with mutant p53. However, 
statistical analysis using Fisher’s exact test (Table 12) showed no statistical 
significance (p= 0.53). Unfortunately due to the limited amount of clinical
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No.patients Tai^et tumour response
PR MR SD Prog
p-value
Baseline neutralising Positive 13 1 2 3 7
antibody levels Negative 9 2 0 5 2 0.96
p53 gene sequence Mutant 16 2 2 4 8
Wild type 5 1 0 3 1 0.53
Noninter. 1 0 0 1 0
Table 11. Response to Onyx-015 related to p53 gene sequence and baseline 
neutralising antibody level.
p value based on comparison of tumours showing a response (PR,MR) versus no 
response (SD,Prog). PR,partial response; MR, mi nor response; SD,stable disease; 
Prog, progressive disease.
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No.patients Viral replication by ISH
Positive Negative
p-value
p53 gene sequence Mutant 16 4 12
Wild type 5 0 5 0.53
Noninter. 1 0 1
Table 12. Viral replication related to p53 gene sequence.
p value based on comparison of tumours showing positive staining by in situ 
hybridisation versus no staining.
tissue available from the core biopsies, no attempt was made to culture virus 
from the biopsy specimens.
3.4.5. Humoral immune response and correlation to tumour response.
13 of the 22 patients treated (59%) had pre-existing neutralising 
antibodies to adenovirus and all but one patient developed increased 
antibody levels after treatment. If we compare baseline neutralising antibody 
levels of patients who had evidence of tumour response (MR,PR) to those 
who did not (SD,Prog) statistical analysis using Fisher’s exact test (Table 
11) showed no significant correlation (p=0.96). Therefore pre-existing 
neutralising antibody levels did not determine tumour response.
3.5. PHASE I TRIAL - multiple injection protocol.
3.5.1. Patient characteristics.
The characteristics of the patients treated and their prior therapy is 
shown in Table 13. All 10 patients treated were evaluable for toxicity and 
efficacy. 8 patients were male and 2 were female. The mean age was 66 and 
all patients had a performance score above 60% with a median of 80%. All 
patients had received radiotherapy either alone or in combination with 
surgery and/or chemotherapy. 5 patients had received chemotherapy in 
combination with radiotherapy and surgery. The most common site of 
recurrence was in the neck (regional recurrence) in the cervical area. The 
size of the recurrent tumours varied over a range from 4 cm^ to 7.5 cm^ 
with the mean being 6.2 cm^.
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A getyears) Median 66
Range 44-88
Sex Male 8
Female 2
Performance status 80% 5
70% 3
60% 2
Prior tlierapy S uigery+XRT+C hemo 5
Smgeiy+XRT 4
Radiotherapy alone 1
Location o f recurrence Cervical 5
Facial 2
Oropharynx 3
Tumour size-cm^ Median 6.2
Range 4-7.5
p53 gene sequence Mutant 5
(exons 4-9) Wild type 5
B aseline neutralising antibody Positive 7
levels Negative 3
CD4 counts <500 9
(range 152-1343) >500 1
Table 13. Baseline patient characteristics in multiple injection 
protocol.
A total of 10 tumours were positive for mutant p53 by 
immunohistochemistry. Not all tumours were mutant p53 on gene 
sequencing however. 5 tumours had mutant p53 sequence and 5 had wild 
type p53 sequence. The pre-treatment immune status of each patient, as 
assessed by CD4 lymphocyte count, again showed that most patients were 
immunosuppressed. 9 of the 10 patients had a CD4 count less than 500 
(range 152-1343).
3.5.2. Toxicity and safety
Table 14 summarises the treatments given. Of the 10 patients, 7 
received 1 cycle, 2 received 2 cycles and 1 received 7 cycles. Therefore a 
total of 18 cycles were given. Intratumoural injection of Onyx-015 was 
again well tolerated with no dose limiting toxicity being observed. 
Toxicities probably or possibly related to Onyx-015 are shown in Table 15 
and are all of grades I/II. The most frequent symptom was flu syndrome 
(30%) of Grades I/II. Flu-syndrome was more frequent in the multiple 
injection study at 30% compared to approximately 10% in the single 
injection study. Nausea and diarrhoea were also more frequent with 30% of 
patients experiencing these symptoms compared to 10% in the single 
injection study. This may suggest there was more shedding of virus into the 
circulation in the multiple injection study. Serial blood tests showed no 
myelosuppression. Despite the increased number of injections, pain on 
injection was only reported in 1 patient. Safety studies were also 
encouraging since all blood samples to detect adenovirus by PCR were
Cohort No.patients No.cycles |Target tumour response
1 2 3 4 5 6 7 PR MR SD Prog
SxlO^pfli 4 2 1 0 0 0 0 1 1 0 1 2
5xlO*^ptu 6 5 1 0 0 0 0 0 0 0 4 2
Total 10 7 2 0 0 0 0 I 3 2 8 9
Table 14. Patients treated per cohort and target tumour response at >4 weeks 
using non-conventional measurements in multiple injection protocol.
Toxicity profile - all Grade I/II
Toxicity Cycle 1 All cycles n=18
Nausea 3(30%) 3(17%)
Flu syndrome 3(30%) 3(17%)
Chills 2(20%) 2(11%)
DiaiThoea 2(20%) 2(11%)
Lymphocytopenia 2(20%) 2(11%)
Fever 1(10%) 1(5%)
Vomiting 1(10%) 1(5%)
Pain(tumour) 1(10%) 1(5%)
Table 15. Toxicity profile for multiple injection protocol for first cycle 
and all cycles.
negative and all swabs of the oropharynx and injection sites were negative 
for adenovirus.
3.5.3. Tumour response and correlation to p53 status.
All patients were evaluable for tumour response and these are shown 
in Table 14. Using non-conventional criteria for measuring the degree of 
tumour shrinkage, 1 patient showed a partial response and 5 patients showed 
stable disease in the treated lesion. The patient with a partial response had a 
primary floor of mouth squamous cell cancer treated with surgery and 
radiotherapy. He developed a 4cm x 2cm recurrence in the left cheek and 
this was injected at 5 x 10  ^pfu. An 80% reduction in the tumour occurred 
over 7 cycles of treatment. This patient was removed from study at 28 weeks 
when the target tumour began to progress. Of the 5 patients with stable 
disease, 3 were removed from study at 4 weeks due to the development of a 
second locoregional recurrence. The other 2 patients were removed from 
study at 8 weeks again due to the development of a second locoregional 
recurrence. 4 patients progressed at the injected lesion at 4 weeks post virus 
injection.
The p53 status of tumours versus the tumour response is shown in 
Table 16. The tumour which showed a partial response had mutant p53 on 
gene sequencing. If we again compare the p53 status of tumours showing 
evidence of response (MR,PR) to those which did not (SD,Prog), statistical 
analysis using Fisher’s exact test showed no significant correlation (p=l).
3.5.4. Detection of Onyx-015 in tumour and correlation to p53 status.
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No.patients Target tumour response
PR MR SD Prog
p-value
Baseline neutralisii^ Positive 7 1 0 5 1
antibody levels Negative 3 0 0 0 3 0.98
p53 gene sequence Mutant 5 1 0 3 1
Wild type 5 0 0 2 3 1
Table 16. Response to Onyx-015 related to p53 gene sequence and baseline 
neutralising antibody level.
p value based on comparison of tumours showing a response (PR,MR) versus no 
response (SD,Prog). PR,partial response; MR,minor response; SD,stable 
disease; Prog, progressive disease.
No.patients Viral n
Positive
; plication
Negative
by ISH
No biopsy
p-value
p53 gene sequence Mutant 
Wild type
5
5
2
3
I
1
2
1 0.99
Table 17. Viral replication related to p53 gene sequence.
p value based on comparison of tumours showing positive staining by in situ 
hybridisation versus no staining.
Adenoviral DNA was detected in tumour biopsies by in-situ 
hybridisation. 5 of 7 tumours showed positive evidence of viral replication 
on the biopsies obtained. 3 patients did not have post-treatment biopsies 
carried out. This increased frequency suggested that multiple injections 
resulted in better viral distribution. In contrast to the single injection study, 2 
of the 5 tumours with evidence of viral replication had wild type p53 gene 
sequence. Statistical analysis using Fisher’s exact test (Table 17) again 
showed no significant correlation between replication and p53 gene 
sequence however. (p=0.99).
3.5.5, Humoral immune response and correlation to tumour response.
7 of the 10 patients treated (70%) had pre-existing neutralising 
antibodies to adenovirus and all developed increased antibody levels after 
treatment. If we compare baseline neutralising antibody levels of patients 
who had evidence of tumour response (MR,PR) to those who did not 
(SD,Prog) statistical analysis using Fisher’s exact test (Table 16) showed 
no statistically significant correlation (p=0.98). Therefore pre-existing 
neutralising antibody levels did not determine tumour response.
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Chapter 4
Discussion
4.1. RATIONALE
The E lB  55kDa gene deleted adenovirus,Onyx-015, has been shown 
to selectively replicate in cells with non-functional p53 (Bischoff et al, 
1996). The objective of this thesis was to determine if this virus could be 
used as a new form of therapy for the treatment of recurrent head and neck 
cancer. Current therapies for this disease including reirradiation, 
chemotherapy, chemoradiation have poor response rates and short 
progression free time intervals. It is also a disease which produces 
considerable morbidity with difficulties in speech, swallowing and pain 
control. Therefore a locoregional therapy for this disease, such as 
intratumoural injection of Onyx-015, would be an attractive alternative 
therapy for this disease. Before we could carry out any clinical trials with 
this virus it was first necessary to determine if Onyx-015 could replicate in 
head and neck cancer cell lines both in vitro and in vivo and to determine if 
this was selective for mutant p53 cell lines. For this therapy to be useful in 
head and neck cancer it was also necessary that recurrent head and neck 
cancer had a high incidence of p53 inactivation. No studies have examined 
the p53 status of recurrent disease before and therefore we carried out a 
small study in 22 patients to evaluate the incidence of p53 inactivation by 
mutation, deletion and inactivation by other mechanisms.
4.2. PRECLINICALHNSCC STUDIES.
4.2.1. In-vitro and in-vivo studies.
Previous in-vitro and in-vivo studies had shown that Onyx-015 
would selectively replicate in and lyse tumours with mutant p53 (Bischoff et
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al,1996). No viral studies have been carried out on squamous cell cancer cell 
lines either in-vitro or in-vivo. Using a panel of HNSCC cell lines of known 
p53 sequence we tested for viral induced cytolysis and viral replication 
using CPE assays, hexon protein immunofluorescence and FACS analysis to 
quantitate replication. In agreement with Bischoff et al,1996 we have shown 
all HNSCC cell lines with mutant p53 were susceptible to Onyx-015. The 
only HNSCC cell line tested with wild type p53 was BICR19. This cell line 
has one wild type allele and one mutant p53 allele. FACS analysis showed 
that little replication occurred in this cell line suggesting that only one 
functional allele of p53 may be required to confer resistance to Onyx-015. 
This data was encouraging since recent papers by Ridgeway et al, 1997 ; 
Goodrum and Ornelles,1997 and by Hall et al,1998 had suggested that 
replication of E lB  deleted adenoviruses showed no correlation to p53 status. 
These papers were also controversial since in all three papers the p53 
function of the cell lines used was not fully determined. Goodrum et al, 1997 
suggested that replication was cell cycle dependent and was more productive 
if cells were in S phase of the cell cycle and that this was independent of p53 
status. Hall suggested that viral induced cell death was more efficient in 
wild type p53 cell lines but failed to show the mechanism of cell death, i.e. 
apoptosis or viral replication. Therefore, despite these papers, the hypothesis 
that E lB  attenuated viruses can selectively replicate in cells with non­
functional p53 has not been disproved. Indeed we have recently shown using 
the paired ovarian adenocarcinoma cell lines A2780 (wild type p53 
sequence and function) and A2780Cp70 (wild type p53 sequence but non­
functional) that replication is six fold greater in the Cp70 cell line. However
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we also showed that Onyx-015 could induce apoptosis in A2780 and that 
this was mediated by E l A induction of functional p53. This observation 
could explain some of the findings in the papers by Hall and Goodrum.
The cell line BICR16, derived from a patient with recurrent 
HNSCC, has a point mutation in the p53 gene at codon 146. This cell line 
was used as the in-vivo model for recurrent HNSCC by forming 
subcutaneous xenografts in nude mice. The tumours were injected with 5 
daily injections of either Ad2 or Onyx-015 against a control solution of 
PBS. Tumour regression occurred for both viruses in all tumours. Statistical 
analysis showed a p value of 0.002 (very significant) for the Ad2 group and 
a p value of <0.001 (highly significant) for the Onyx-015 group. 
Furthermore, in-situ hybridisation for viral DNA in these treated tumours 
showed the presence of adenoviral DNA which suggested that regression 
was due to the replication of virus in the tumours. Thus both the in-vitro and 
in-vivo data were very encouraging and suggested that Onyx-015 may be 
efficacious in patients with recurrent HNSCC .
4.2.2. Preclinical p53 HNSCC studies.
Our next objective was to determine the incidence of p53 
inactivation in recurrent HNSCC since for Onyx viral therapy to be 
successful it was necessary that tumours had non-functional p53. We 
studied 22 recurrent tumours and have shown that in recurrent HNSCC there 
is a high incidence of p53 mutation. 15 of the 22 tumours (68%) had either a 
p53 mutation or deletion. Of these, 6 were missense mutations whereas 9 
had nonsense inactivation. The immunohistochemistry results correlated
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very well with the mutations seen. Previous studies in primary head and 
neck cancer have shown an incidence of p53 mutation of 38% -53% ( Boyle 
et al,1993; Brachmann et al,1992; Koh et al,1998; Mao et al,1996; Olshan et 
al,1997). It has been suggested that p53 mutation is an early event in head 
and neck carcinogenesis. Boyle et al,1993 showed an incidence of mutation 
of 19% in preinvasive lesions increasing to 43% in invasive lesions. 
However, Chung et al,1993 showed that the frequency of p53 mutations did 
not increase with stage of disease with a reported incidence of 47% in stage 
I/II disease and 37% in Stage III/IV disease. In our study, we have reported 
an incidence of p53 mutation in recurrent HNSCC of 68% which is higher 
than that reported for primary disease. We did not carry out microdissection 
of tumour cells from surrounding normal cells in the preparation of tumour 
DNA so it is possible that some tumours with wild type p53 gene sequence 
are in fact false negatives and therefore the incidence may be higher than 
68%. Our figures (and those reported for primary disease by other studies) 
are also based upon sequencing exons 4-9 of the p53 gene. Although 95% of 
mutations occur in these exons, some mutations occur in intron regions and 
also other exons. Therefore the incidence of p53 mutations in our study may 
be higher. Similarly the incidence in previously published studies on 
primary head and neck cancer may also be slightly higher than 38-53%. It is 
also possible that previous studies have underestimated the incidence of p53 
mutation due to the heterozygous nature of primary tumours resulting in 
false negative results on gene sequencing. In recurrent tumours, clonal 
expansion of tumour cells refractory to radiotherapy occurs and therefore the 
pickup rate for detecting p53 mutation may be more accurate. However,
94
another possibility may be the induction of p53 mutations by radiotherapy 
treatment itself since radiation is a potent DNA damaging agent and induces 
single and multiple base pair deletions in DNA. It is difficult to distinguish 
between these 2 possibilities but one method could be to prepare molecular 
probes to the p53 mutation in each recurrent tumour and then to use these 
probes to screen the primary tumours to look for the mutation.
p53 can be inactivated by human papilloma virus (HPV) due to the 
ability of HPV E6 protein to bind to and promote the degradation of the 
product of the p53 gene (Levine,1990; zur Hausen,1994). Indeed 
inactivation of p53 by HPV E6 is the major mechanism of p53 inactivation 
in cervical carcinogenesis (zur Hausen,1994) with approximately 80-90% of 
cervical cancers containing HPV DNA (Yoshikawa,1991). Previous studies 
have shown HPV DNA in tumours of the head and neck but its prevalence 
varies from 10-58% (Paz et al,1997; Haraf et al,1996; Miguel et al,1998; 
Koh et al,1998). A metanalysis by McKaig et al,1998 showed an overall 
incidence of 34.5% with the predominant type being HPV 16. The incidence 
also varies with tumour site with the highest prevalence being in tonsillar 
carcinoma (Paz et al,1997). In our study in recurrent tumours of the head 
and neck, we found an overall incidence of 36% (8/22), all of which were 
HPV 16. These results were very similar to the metanalysis figures by 
McKaig for primary tumours and this would suggest that HPV infection is 
not a major aetiological factor in recurrent disease. One of the limitations of 
our study, and of previously published studies, is that HPV detection is 
based upon PCR analysis of HPV DNA and not mRNA of HPV E6-E7 
regions. It is possible that PCR analysis of HPV DNA can overestimate the
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presence of HPV due to cross contamination resulting in false positives. 
Since RNA is readily degradable, cross contamination is less likely to result 
in false positives. Another advantage of using RNA is that it proves that any 
HPV present in tumour cells is actually expressed at the mRNA level. Some 
studies have reported HPV detection by detecting mRNA using in-situ 
hybridisation of paraffin embedded samples ( Stoler et al,1992). A more 
accurate method however is to use RTPCR as reported by Czegledy et 
al,1995. In our study, DNA was used because the samples used were too 
small to allow an adequate amount of RNA to be prepared. Of the 8 tumours 
which were positive for HPV, 5 tumours were in tumours with mutant p53 
and 3 were in tumours with wild type p53. These figures are similar to those 
in primary tumours as reported by Koh et al,1998 and suggests that p53 
mutation and HPV positivity are not mutually exclusive mechanisms of p53 
inactivation. This is in contrast to cervical carcinogenesis where p53 
mutations are rare in cases with HPV but common in malignancies devoid 
of HPV infection (Crook et al,1991; Park et al,1994).
Another factor which can inactivate p53 is the cellular protein 
mdm2. Mdm2 inhibits the transcriptional activity of p53 by binding to the N 
terminus of p53 (Haupt et al,1997) which in turn leads to the degradation of 
p53 via the ubiquitin degradation pathway. Thus amplification or 
overexpression of mdm2 can cause p53 inactivation (Oliner et al,1992). In 
primary HNSCC, mdm2 overexpression is reported to be 40% (Matsumura 
et al,1996). Girod et al,1995 showed an increase in mdm2 expression from 
premalignant to malignant lesions indicating that this may be a mechanism 
for inactivation of p53 early in head and neck carcinogenesis. Further
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evidence to suggest this was reported by Pruneri et al,1997 who showed that 
out of 17 laryngeal tumours overexpressing mdm2, 10 of these also 
overexpressed p53 and all ten had wild type p53 sequence. The importance 
of mdm2 overexpression in recurrent HNSCC is unknown. In the small 
group of tumours which we have studied, we have shown an incidence of 
50% of which 5/11 were weakly positive and 6/11 were strongly positive for 
mdm2. Mdm2 overexpression was present in 7 tumours with mutant p53 
and in 4 tumours with wild type p53 and this also suggests that p53 mutation 
and mdm2 overexpression are not mutually exclusive mechanisms of p53 
inactivation. A particularly intriguing observation is that of the 7 tumours 
which had wild type p53 sequence, 6 were positive for either HPV infection, 
mdm2 overexpression or both. Thus in wild type p53 tumours, the p53 gene 
is inactivated by other mechanisms making the overall incidence of p53 
inactivation in recurrent HNSCC in this study to be 95% (21 out of 22 
tumours). It is unclear whether or not this overall incidence is greater than 
primary HNSCC since no study has ever examined p53 mutation, HPV 
infection and mdm2 overexpression in the same group of tumours. The 
observation that the incidence of HPV infection and mdm2 overexpression 
are similar to primary disease indicates that these factors have a limited role 
in the aetiology of recurrent HNSCC but may be more important in tumours 
in which the p53 gene is not inactivated by mutation.
The observation that recurrent disease has a very high incidence of 
p53 inactivation is clearly important as p53 is central to apoptosis induced 
by radiation and many chemotherapeutic agents. This may account for the 
poor response of these tumours to both reirradiation and chemotherapy.
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Therefore, new therapies which can restore p53 functionality, such as 
adenoviral mediated transfer of wild type p53 (Roth et al, 1996), may be 
beneficial in this disease. Indeed, in-vitro and in-vivo studies using such a 
technique have demonstrated growth suppression in HNSCC cell lines ( Liu 
et al ,1994, Liu et al ,1995; daym an et al, 1995). Results of a phase I study 
in patients with recurrent HNSCC were also recently reported (daym an et 
al,1998) and this showed evidence of tumour necrosis in some patients. 
Other methods of restoring p53 function could be to use small molecules to 
inactivate the mdm2 protein ( Bottger et al,1998), or drugs which interfere 
with HPVE6 binding to wild type p53 thus restoring function of p53. Other 
approaches to the treatment of this disease may be to use drugs which act in 
a p53 independent manner. For example, Taxanes (Taxol) act by inducing 
p53 independent apoptosis and have been successful in the treatment of 
refractory cisplatin resistant ovarian cancer, a disease where there is also a 
high incidence of p53 inactivation (Righetti et al,1996; Buttitta et al,1997). 
Catimel et al,1994 has shown this agent to be effective in recurrent HNSCC 
but there is no evidence yet that it has increased benefit over cisplatin / 5FU 
chemotherapy. However newer agents which act in a p53 independent 
manner may prove to be more beneficial. Our approach has been to use the 
selectively replicating adenovirus Onyx-015 which has been shown to 
selectively destroy tumours with non-functional p53. Since we have shown a 
high incidence of p53 inactivation in this disease, Onyx-015 should 
theoretically replicate in and destroy these tumours in patients. We therefore 
carried out a phase I trial using this agent in recurrent HNSCC.
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4.3. CLINICAL PHASE I TRIAL - single injection protocol.
4.3.1. Lack of toxicity
The primary objective of the phase I study was to determine the 
safety of a single injection of Onyx-015 by intratumoural injection in 
patients with recurrent HNSCC. The results obtained showed that toxicity 
was very minor, with the main symptoms being mild flu-like symptoms. 
Two patients did experience mild pain on injection and this was related to 
the volume of injected solution. The pain resolved within 1 hour and rarely 
required any further analgesia. The maximum dose injected was lO^^pfu and 
this did not produce any serious adverse effects. The maximum tolerated 
dose was clearly not reached in this study, but dose escalation ceased 
because the limit of virus manufacturing capacity had been reached. This 
lack of toxicity is very encouraging and suggests that perhaps more potent 
replicating viruses can be explored in future trials. Safety data were also 
encouraging since no virus was detected in either blood samples or injection 
site and oropharyngeal swabs and this suggested that virus shedding was not 
a major issue. This was in agreement with a previous study which involved 
the intratumoural injection of a replication incompetent adenovirus Ad5p53 
in patients with recurrent head and neck cancer (Clayman et al,1998). In this 
study adenovirus was detectable in blood samples by PCR at 30-90 minutes 
post virus injection but was undetectable by 48 hours. In our study the 
earliest sample was at 72 hours post injection and all were negative for 
adenovirus. Thus both studies show virus is undetectable after 48-72 hours 
post virus injection.
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4.3.2. Evidence for antitumoural activity.
One of the secondary objectives of the study was to determine if 
there was evidence of an antitumour effect. This was assessed both clinically 
and radiographically by either CT or MRI scans. Ultimately, all patients in 
the study progressed due to the development of other neck lesions or due to 
distant métastasés in the lung, liver or bone. However, if we consider only 
the tumours which were injected, then there was evidence of antitumour 
activity. Using non-conventional measurements, 5 (23%) patients showed 
either a partial or minor response, while a further 8 (36%) showed stable 
disease. Of the 5 patients who showed evidence of tumour response, 4 had 
mutant p53 suggesting a correlation between p53 status and tumour 
response. 1 patient had wild type p53 sequence, but it is possible that in this 
patient’s tumour the p53 protein was inactivated by either HPV infection 
(Lechner,1992; Scheffner et al,1992), mdm2 overexpression (Barak et 
al,1993; Oliner et al,1992) or by some other factors. Alternatively, a 
mutation of the p53 gene may have been present outside exons 4-9 or in the 
intron regions. Despite this observation, statistical analysis of p53 status and 
tumour response showed no significant correlation however.
The cause of the clinical and radiological changes in keeping with 
necrosis in responding patients is most likely as a result of injection of 
Onyx-015 since diluent injected tumours showed no evidence of necrosis. 
These changes may be due to viral replication and spread. However, it may 
also be possible that some of the observed response is due to an immune 
response against virally infected tumour cells.
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4.3.3. Efficiency of viral replication
Viral replication was detected in patient biopsies by in-situ 
hybridisation techniques. Although the presence of viral DNA is not 
definitive evidence of viral replication it is suggestive that replication is 
occurring. Positive evidence of viral DNA was found in 4 patients, all of 
whom had mutant p53 tumours. No replication was detected in tumours with 
wild type p53 or in surrounding normal tissue. This supported the hypothesis 
that Onyx-015 selectively replicated in mutant p53 cells. However the 
correlation between p53 status and viral replication was not statistically 
significant. Interestingly other tumours with mutant p53 did not show 
evidence of virus by in-situ hybridisation. There are several possible 
explanations for this. It may be that Onyx-015 does not have the rigid 
selectivity for p53 mutant tumours as suggested by Bischoff et al,1996. 
Indeed recent studies (Goodrum et al,1997; Hall et al,1998) have shown no 
correlation between p53 status and viral replication in cell lines of known 
p53 status. Even these studies were controversial however since the p53 
functional status of the cell lines used had not been fully determined and the 
mechanism of cell death (i.e. apoptosis versus viral replication) had not been 
fully established. Using the matched colon cancer cell lines 
RKO/RKOp53.13, Bischoff et al,1996 reported reduced replication of 
Onyx-015 virus in the p53 transfectant cell line using burst assays as the 
measure of replication. In contrast. Hall et al,1998 reported no difference in 
replication in the same cell lines, and a second matched pair of cell lines 
HT1080/HT1080-6TGc5, using cytopathic effect assays as their measure of 
replication. The authors however, did not determine the mechanism of cell
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death i.e. viral induced cytolysis versus apoptosis and did not produce a 
quantitative measure of viral replication. These different methods of 
assaying viral induced cell death may account for the apparently conflicting 
results obtained in these papers. The clinical study presented in this thesis on 
head and neck cancer patients has not resolved this controversial issue. It is 
also possible that the low detection rate of viral replication in mutant p53 
tumours may also have been due to the sensitivity and specificity of the 
technique used. For example, the tumour biopsies were very small compared 
to the size of the injected tumours (<1%) and therefore the area of tumour 
which was injected may not have been biopsied in the majority of cases. In 
animal experiments, replication was evident in nude mouse human tumour 
xenografts in the cells at the watershed between necrosis and viable tumour 
(Heise et al,1999). Since it is not possible to biopsy necrotic tissue 
effectively, it is not surprising that biopsies of viable tumour did not show 
replication. In addition, animal studies in nude mice have shown that 
distribution is better with a multi-injection protocol (Heise et al,1999). It is 
also possible that viral spread is limited by the fibrotic nature of these 
tumours since the majority of patients had previously been treated with 
external beam radiotherapy.
Lastly, it is possible that viral spread is affected by systemic or local 
immune effects. Adenovirus can produce two systemic immune effects - cell 
mediated and humoral immunity. Cell mediated immunity is mediated by 
cytotoxic T lymphocytes and is stimulated by adenovirus antigens produced 
in the host cell and presented along with MHC moitiés on the cell surface. 
This can cause early elimination of virus but may also be beneficial as it
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causes the immune mediated killing of tumour cells. In this clinical study, 
all patients were immunosuppressed at baseline with low total lymphocyte 
counts and low CD4 counts. A total of 19 patients had a CD4 count less than 
500 with a median range of 200-300. To determine whether or not a cellular 
immune response occurred, biopsy specimens were stained for helper T 
lymphocytes (CD4), cytotoxic T lymphocytes (CDS) and for macrophage 
infiltration (CD68). However, because the biopsies were so small it was not 
possible to make any conclusions as to the relevence of a cellular response 
to overall tumour response. We are currently planning to carry out a pre­
operative study on patients with early stage HNSCC in which patients 
receive a single intratumoural injection of virus within the first 2 weeks 
prior to definitive surgery. It will then be possible to examine whole tumour 
sections once the tumour is excised to determine the extent of viral spread 
and immune effector cell response.
The neutralising antibody response (humoral response) to adenovirus 
occurs later. Theoretically, this should reduce the ability to reinfect host 
cells with adenovirus after first inoculation. In this study, all patients 
developed a rising neutralising antibody response despite being 
immunosuppressed. Statistical analysis showed no correlation between 
pretreatment antibody levels and tumour response. In addition, patients who 
were retreated continued to show a response despite rising antibody levels. 
This data would suggest that neutralising antibody to adenovirus may not be 
clinically relevant to intratumoural efficacy. There is also some evidence 
that suggests that antibody penetration into these tumours may be minimal 
(Jain,1994; Dvorak et al,1988), in which case a rising antibody would have
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no effect in a repeat intratumoural administration procedure and would only 
be of importance in repeat systemic viral injection. If humoral immunity 
proved to be troublesome, it is possible to suppress this with y-interferon 
and IL-12 (Yang et al,1995), by using viruses with non-crossreactive 
serotypes (Mastrangeli et al,1996), or by creating viruses which are 
encapsulated in poly(lactic-glycolic) acid copolymer (PLGA) to evade the 
immune system (Beer et al,1997).
Local immunity, as well as systemic immunity, is also a factor 
which may limit viral spread. Tumours secreting interferon may neutralise 
viral spread. It has recently been shown that adenovirus infection stimulates 
the activation of the transcription factor NFkB which results in a 
downstream inflammatory response (ICAM-I up-regulation) 
(Clesham,1998). It has also been shown that adenovirus infection causes 
stimulation of the Raf/MAPK pathway and IL-8 secretion (Bruder et 
al,1997). Experiments to investigate the role of the immune system are 
planned with a pre-operative study in patients with early stage HNSCC.
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4.4. CLINICAL PHASE I TRIAL - multiple injection protocol.
Preclinical data suggested that multiple injections of vims may be 
more effective (Heise, unpublished results). A daily x 5 multiple 
intratumoural injection study was therefore carried out following the single 
injection study.
The primary objective of the multiple injection protocol was to 
determine the safety of Onyx-015 injection by intratumoural injection and to 
compare this to toxicity observed in the single injection protocol. The results 
showed that there was an increase in flu-like symptoms in the multiple 
injection study. 30% of patients reported these symptoms compared to 10% 
in the single injection study. However, although more patients reported these 
symptoms, the grade of toxicity remained at Grade I/II. The increase in flu­
like symptoms suggested that this may be due to viral shedding into the 
circulation. However, PCR analysis of blood from all patients did not detect 
any evidence of adenovirus. These flu-like symptoms again only lasted for a 
period of 48 hours before they settled. Surprisingly, there was no increase in 
the reported incidence of pain on injection despite the fact that the patients 
received repeat injections into the same site over 5 successive days. 
Therefore, overall the multiple dose injection procedure was well tolerated 
and was as safe as the single injection procedure.
When we examined tumour biopsies for viral replication by in-situ 
hybridisation, virus was detected in 5 of 7 patients (3 patients did not have 
post-treatment biopsies). This was substantially greater than the single 
injection protocol where only 4 of 22 patients had positive biopsies. In 
addition, the percentage number of cells staining positively for virus was
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greater and the distribution of virus more uniform compared to the single 
injection protocol. Therefore, overall the multiple injection protocol gave 
better viral distribution compared to the single injection protocol. Unlike the 
single injection study, 2 of the 5 patients with evidence of viral replication 
had wild type p53 on gene sequencing. This does not discount the selectivity 
for Onyx-015 to replicate only in mutant p53 tumours since it is possible 
that the 2 tumours with wild type p53 had mutations outside exons 4-9 or 
p53 may have been inactivated by other mechanisms such as mdm2 
overexpression or HPV infection.
Although the multiple injection study produced better viral 
distribution, this did not result in an increase in efficacy in the limited 
number of patients studied. Of the 10 patients treated, only 1 patient had a 
partial response and this was at a dose of 5 x 10  ^pfu. This patient received 7 
cycles of treatment resulting in an 80% reduction in tumour size but was 
eventually removed from study at 28 weeks when the target tumour began to 
progress. Because only a limited number of patients were studied with 
multiple injections, we cannot draw any conclusions regarding efficacy and 
therefore a larger phase II study is planned to further evaluate efficacy with 
the multiple injection protocol.
4.5. FURTHER DEVELOPMENTS.
In summary we have shown that intratumoural injection of the ElB  
attenuated replicating adenovirus, Onyx-015, is feasible and safe with very 
limited toxicity. Although no objective tumour responses were observed, 
evidence for biological activity was observed. However, response did not
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correlate significantly with the p53 status of injected tumour. In addition, 
although viral replication was found only in tumours with mutant p53 and 
not in normal cells, the relationship between p53 status and viral replication 
was not statistically significant. This may have been due to limitations in the 
techniques used to assess replication but does not exclude the possibility that 
the selective replication of Onyx-015 for p53 mutant tumours is not as 
stringent as first thought. Further studies in patients are therefore required to 
resolve this issue. Nevertheless the observation of biological activity of this 
agent in recurrent head and neck cancer patients is encouraging. Current 
available therapies for recurrent head and neck cancer, such as tumour 
debulking surgery, further radiation and chemotherapy have all produced 
poor responses of limited duration. All these therapies also produce 
significant morbidity. An agent such as Onyx-015, which has very little 
toxicity and which can be given as an outpatient without the need for 
hospitalisation, may be an attractive alternative to these therapies but only if 
responses are comparable. Further studies are therefore warranted to further 
evaluate this form of therapy for this disease. Several potential clinical 
applications exist for this new form of therapy. Since p53 mutation is the 
commonest genetic alteration in human cancers, E lB  551Æ) gene- deleted 
adenoviruses may be of importance in the treatment of a wide range of 
human cancers. It may be of use in the local control of recurrent HNSCC, a 
disease for which currently available therapies are of little benefit. In 
addition, it may be useful for the treatment of minimal residual disease in 
head and neck cancer. The commonest cause of treatment failure in head and 
neck cancer is locoregional recurrence and the single most important factor
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responsible for this is incomplete surgical margins (Snow,1989). It is now 
possible to detect 1 tumour cell out of 10,000 in resection margins using a 
molecular probe against the patient’s mutant p53 (Brennan et al,1995). 
Therefore it may be possible that patients with positive margins using this 
molecular probe could be treated by direct injection of the surgical margins 
or bathing the surgical bed with Onyx-015 to prevent local tumour 
recurrence.
Malignant glioma and ovarian cancer are other tumours in which 
p53 mutations are frequently seen and which may be amenable to local or 
regional injections. Phase I studies in these cancers and others are currently 
underway. Recent work has also shown that combination therapy with 
Onyx-015 and chemotherapeutic agents such as cisplatin and 5-Fluorouracil 
(5FU) was superior to treatment with either agent alone when tested in nude 
mouse xenograft tumours (Heise et al,1997). A clinical trial of cisplatin/5FU 
combined with Onyx-015 has recently started in patients with recurrent 
head and neck cancer and early results are encouraging (Nemunaitis et 
al,1998).
Much research is also underway to try to improve the efficacy of 
these oncolytic adenoviruses in cancer therapy, particularly in the areas of 
delivery, intratumoural spread and modulating the immune system (as 
mentioned before). Although direct intratumoural injection of virus is useful 
for the treatment of local tumour disease, tumour targeting is required for 
the systemic treatment of distant metastatic disease. Some targeting occurs 
naturally because the capillaries present in tumours are more leaky than in 
normal tissue and this allows adenoviral particles to selectively concentrate
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in the tumour. However, active tumour targeting can also be achieved by 
attaching ligands, such as epidermal growth factor or basic fibroblast growth 
factor, to the capsid of the adenovirus (Gu et al,1999; Curiel,1999). 
Alternatively, the adenovirus fibre protein can be modified to present a 
tumour specific ligand such as the RGD (Arg-Gly-Asp) motif (Dmitriev et 
al,1998). As well as delivery, much research is currently being carried out to 
improve intratumoural spread of adenovirus. This can be enhanced by 
increasing diffusion of the virus, increasing tropism or increasing the lytic 
effect of the virus. Diffusion can be enhanced by combining virus injection 
with hyaluronidase, heat, radiation or vasodilator drugs. Tropism can be 
enhanced by inserting peptides onto the adenoviral fibre, such as stretches of 
lysines to bind heparin sulphate receptors as well as RGD motifs to bind to 
av  integrins (Dmitriev et al,1998; Staba et al,2000), However such viruses 
may also lose some of their selectivity causing unwanted toxicity. The lytic 
efficiency of the adenovirus can also be improved by deleting the anti- 
apoptotic E lB “19kDa adenoviral gene as well as the E lB  55kDa gene. Such 
a virus has been shown to induce more apoptosis, is released earlier, and 
spreads faster than wild type virus (Sauthoff et al,2000), However, again 
toxicity in normal cells may be increased using this approach. Therefore, 
rather than deleting viral inhibitors of cell death, one could try to enhance 
the lytic effect of adenovirus by increasing the expression of the adenoviral 
E3 11.6kDa death protein (Tollefson et al,1996).
In conclusion, the results presented in this thesis are encouraging for 
the future development of adenoviruses in cancer treatment. However much 
more research is required to improve viral replication, targeting,
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intratumoural spread as well as modulation of the immune system before 
these therapies could be described as the new cancer magic bullet.
no
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